Venture to Venture M&A: Strategic Consolidation in European HealthTech and MedTech Strategic Consolidation in European Healthtech and Medtech: An Analytical Assessment of Venture-to-Venture Tuck In Trends The European healthcare technology and services landscape has entered a structurally distinct phase of maturation, transitioning from the speculative, growth-at-all-costs venture capital paradigms of the post-pandemic era into an era defined by profitable efficiency, clinical validation and platform scale. Following several years of valuation corrections and capital constraints, mergers and acquisitions have become the dominant, necessary exit route for maturing enterprises, consistently and overwhelmingly outperforming initial public offerings by volume. Within this overarching consolidation wave, venture-to-venture "tuck-in" transactions, where late-stage, well capitalised digital health scale-ups acquire early-stage, highly specialised startups, have experienced a marked acceleration. This shift represents a strategic pivot away from funding isolated, single-purpose point solutions and toward the integration of robust, multi-product enterprise platforms capable of delivering quantifiable clinical and operational returns to overstretched health systems. The Industrialisation of Healthcare: Macroeconomic and Regulatory Drivers The acceleration of tuck-in transactions across Europe is driven by a convergence of severe macroeconomic pressures, evolving regulatory frameworks, and shifting capital-market dynamics. These forces have combined to create a unique pressure cooker for consolidation, which industry analysts have termed the industrialisation of care. The Regulatory Sandbox and Compliance Barriers The implementation of rigorous European regulatory frameworks has acted as an artificial clearing mechanism in the healthtech sector. Evolving compliance mandates, such as the full implementation of the EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR), have created capital intensive barriers to entry. The substantial costs associated with obtaining Notified Body certification and generating continuous clinical data act as a strategic barrier for undercapitalised Small and Medium-sized Enterprises (SMEs), driving them into the arms of larger platforms with scaled regulatory departments. Simultaneously, the introduction of the new EU AI Act and the Digital Omnibus package, which outlines the "Data Unlock" concept to streamline the interaction between AI governance, MDR and GDPR, places complex compliance requirements on high-risk artificial intelligence systems. Smaller startups, unable to absorb these compliance overheads, increasingly seek integration with larger strategic entities. Private Equity Liquidity Dynamics and Arbitrage While regulatory barriers constrain early-stage independent survival, the massive capital overhang within the private equity and venture capital ecosystems provides the necessary liquidity to execute consolidations. Sponsors are under immense pressure to return capital to Limited Partners. With the public IPO window remaining selective, sponsors are increasingly utilising continuation funds and secondary buyouts to extend their holding periods over high-performing platform assets. These platforms act as consolidation engines, executing "buy-and-build" strategies that capitalise on multiple arbitrage. By acquiring smaller competitors at lower multiples, typically x6 to x8 EBITDA and integrating them into a larger platform valued at a premium of x12 to x15 EBITDA, sponsors can drive significant non-organic value creation. Quantitative Assessment of Market Activity The transition from fragmented growth to structured scale is reflected in global and regional transaction volumes, average deal sizes, and capital allocation trends. Financial Metrics and Exit Ratios The primary quantitative metrics of the healthtech and medtech sectors demonstrate a clear consolidation trajectory. Metric Historical Value Current/Observed Value Strategic Significance Sources Global Digital Health Exits 113 Total (H1 2025) 107 M&A vs. 6 IPOs Outlines the unassailable dominance of M&A (94.7% of exits) over public listings Various Average Healthtech Deal Size $13.6 Million (Q1 2022) $46.6 Million (Q1 2026) Demonstrates a shift away from early-stage testing to late-stage platform scale Various European Digital Health Funding ~$1.1 Billion (Q1 2024) ~$2.0 Billion (Q1 2025) Reflects a major rebound (82% YoY) focused on platform scale and integration Various Global Venture Capital Funding $12.1 Billion (Historical) $15.3 Billion (Recent YoY) Indicates a market recovery (26% YoY increase) driven by larger, AI-powered rounds Various Private Equity Dry Powder $2.0 Trillion (Historical) $2.5 Trillion (Current Overhang) Underpins massive capital availability for programmatic buy-and-build strategies Various Platform Valuation Multiples 6x - 8x EBITDA (Target) 12x–15x EBITDA (Platform) Illustrates the multiple arbitrage driving private equity-backed consolidation Various Regional M&A Architecture and Geographic Bifurcation Consolidation maturity varies across European geographies. In highly integrated markets, such as the Netherlands and the United Kingdom, consolidation is advanced. The strategic focus in these regions has shifted toward secondary buyouts, the creation of pan-European "super-platforms," and operational optimisation. Conversely, in Southern and Eastern Europe, the market remains highly fragmented, offering attractive entry multiples relative to the saturated Northern and Nordic markets. Spain has emerged as a key gateway for cross-border transactions, bucking broader European downturns with a robust healthcare M&A market. Geographic Region Market Maturity & Strategic Focus Notable Subsector Allocation Transaction Dynamics Sources United Kingdom & Netherlands Advanced maturity; focus on secondary buyouts and super-platform creation Integrated care, primary care booking SaaS, telecare High concentration of corporate clinical groups Various Spain (Southern Europe) Highly active gateway; dynamic domestic and cross-border consolidation Hospitals & Clinics (36.4%), Elderly Care (18.2%), Medtech (13.7%) Balance of 52% strategic and 48% financial buyers Various Nordic Region (Sweden/Finland) Mature innovation hub; focus on outbound strategic acquisitions and wearables Digital therapeutics, mental health platforms, biometric hardware Programmatic cross-border acquisitions Various Rather than deploying entirely cash on balance sheet models, acquirers rely on structured transaction components. Performance-contingent earn outs, representing approximately twenty to thirty percent of total deal value, are increasingly standard in digital health acquisitions where steep revenue trajectories remain unproven or tied to complex public reimbursement pathways. Additionally, minority equity rollovers require founders of acquired startups to roll over thirty to forty percent of their equity into the parent platform, thereby limiting initial cash expenditures for the acquirer while maintaining strategic alignment during subsequent integration phases. Finally, vendor financing is utilised in specialised private equity and strategic consolidator scenarios, where sellers extend credit to the buyer to facilitate the completion of the transaction under tight debt-market conditions. Strategic Anatomy of the Ten Key Transactions The venture-to-venture consolidations executed in the European digital health and medical technology ecosystems reveal distinct strategic pathways. The table below outlines ten prominent examples of European healthtech platforms acquiring peer startups to establish scale, expand functionality, and secure market dominance. Platform Acquirer Target Venture Transaction Date Primary Specialisation Key Operational Metrics & Financials Sources Huma eConsult October 2, 2024 Primary & urgent care digital triage Est. valuation $29M–$43M; based on 50M consultations Various Huma Alcedis January 9, 2023 Data-driven clinical trial technology Combined 1,000 studies across 60+ countries Various Huma iPLATO January 2022 Patient engagement & myGP scheduling Undisclosed value; £3.5M central NHS contract Various Mindler ieso Digital Health UK August 20, 2025 Telecare & typed CBT clinical platform Est. £20M deal; 145,000 patients served Various Mindler Medified Prior to 2025 Mental health outcome tracking SaaS Integrated outcome analytics architecture Various Doctolib Siilo March 2, 2023 Secure healthcare provider messaging Largest European professional chat app Various Doctolib Tanker January 2022 Cryptographic end-to-end encryption Secure communications infrastructure Various Unmind Frankie Health February 2023 B2B personal mental resilience software $1.25M target funding; 1,000+ therapist network Various ŌURA Veri September 11, 2024 Metabolic health & continuous CGM tracking Share exchange; ŌURA $11B corporate valuation Various Mediktor Sensely June 5, 2024 Conversational AI & medical virtual avatars Combined global diagnostic avatar network Various The Huma Ecosystem: Consolidating Patient Monitoring, Engagement and Research Huma has systematically executed a platform consolidation strategy, acquiring three highly complementary UK and German healthcare ventures to build a comprehensive, end to end technology platform for proactive care and clinical research. This programmatic acquisition strategy was supported by Huma's $80 Million Series D funding round, which brought its total funding to over $300 Million. The acquisition of primary care digital triage platform eConsult allowed Huma to integrate automated triage capabilities into its "Huma Workspace" platform. eConsult, which serves more than 1,800 GP practices and has delivered over 50 million digital consultations, provides a critical entry point for patient care. By integrating eConsult's clinical triage technology, Huma created an integrated patient pathway that guides individuals from initial triage to automated remote patient monitoring and virtual ward environments. This integrated system is embedded directly into the NHS App, providing a unified access point for patients and healthcare providers. This primary care strategy was further reinforced by Huma's earlier acquisition of patient engagement specialist iPLATO. iPLATO's myGP platform, which holds key NHS primary care contracts, brought deep patient engagement and communication capabilities to the Huma group. The transaction allowed Huma to combine its acute-care remote monitoring services with iPLATO's scheduling and clinical communication tools, expanding its reach across primary care networks. Simultaneously, Huma expanded its pharmaceutical services through the acquisition of Frankfurt-based Alcedis. Alcedis brought over 25 years of experience in data-driven clinical research and hybrid trial technology. By combining Huma's remote monitoring technology with Alcedis's operational expertise, Huma established a dedicated clinical trials division. The combined entity has managed nearly 1,000 studies across 60 countries, demonstrating how a unified healthtech platform can collect real-world clinical data and manage complex trials at scale. Mental Health Integration: Mindler and Unmind's Platform Strategies The digital mental health sector is consolidating rapidly as platforms move away from simple wellness applications and toward clinically validated, integrated care models. Stockholm-headquartered digital therapy provider Mindler demonstrated this trend by acquiring the UK telecare business of ieso Digital Health. ieso's UK business had supported over 145,000 patients and delivered more than 640,000 hours of cognitive behavioral therapy (CBT) across one third of England's Integrated Care Systems (ICSs). The acquisition, estimated at £20 Million, allowed Mindler to combine its video-based digital therapy platform with ieso’s typed CBT interface and clinical AI tools. This integrated model helps address capacity constraints in the UK, where 11.3% of mental health roles remain vacant and patients face long waiting lists. To support these clinical pathways, Mindler also acquired Finnish outcome-analytics startup Medified, embedding objective, patient-reported tracking software directly into its therapeutic platform. This clinical integration strategy is mirrored in the employer-sponsored wellness sector. Workplace mental health platform Unmind, which has raised $109 Million in funding, acquired Dublin-based Frankie Health to launch its "Unmind Talk" service. Frankie Health brought a personalized mental health platform, a network of over 1,000 licensed therapists, and clinical scheduling technology to Unmind. The integration allowed Unmind to expand its offering beyond preventative wellness tools, providing employees with direct access to clinical therapy and crisis support. Peer-reviewed trials of the integrated platform indicate that these personalized interventions can improve employee productivity by an average of 12%. Secure Communications and Cryptography: The Doctolib Playbook Doctolib, a leading European e-health platform, has utilized acquisitions to expand its core scheduling platform into secure clinical communications and data protection. Doctolib acquired Amsterdam-based secure messaging startup Siilo, the largest professional medical messaging application in Europe. Siilo's platform enables secure, HIPAA- and GDPR-compliant communication among healthcare professionals. By integrating Siilo’s secure messaging tools, Doctolib launched "Doctolib Teams," enabling clinical collaboration, case discussion, and care coordination within its broader booking ecosystem. This secure communication network is supported by Doctolib’s earlier acquisition of French cryptographic startup Tanker. Tanker developed end-to-end data encryption protocols designed to secure sensitive health records. Integrating Tanker’s encryption technology allowed Doctolib to establish high medical confidentiality and data privacy standards across its entire platform, helping the company meet strict European healthcare data requirements as it expanded into new geographies. Biometric Wearables and AI Diagnostics: Oura and Mediktor In the biometric wearables and clinical diagnostics sectors, tuck-in transactions are being used to integrate hardware and software capabilities. Finnish smart-ring pioneer ŌURA, which reached an $11 Billion valuation following a $900 Million Series E funding round, acquired continuous glucose monitoring (CGM) analytics developer Veri. Veri developed software that pairs with CGM sensors to help users analyze how diet and lifestyle choice impact metabolic health. The acquisition allowed ŌURA to integrate Veri’s metabolic tracking software with the Oura Ring's passive biometric monitoring. This software integration supported the launch of the "Meals" feature within the Oura App, enabling users to track meal timing and understand how diet affects sleep, stress, and recovery. This transaction fits into ŌURA’s broader programmatic acquisition strategy, which includes digital identity startup Proxy, performance analytics platform Sparta Science, and gesture recognition pioneer Doublepoint. In clinical diagnostics, Barcelona-based Mediktor acquired San Francisco-based Sensely, a pioneer in empathy-driven conversational AI. Mediktor developed a highly accurate, clinically validated AI symptom-checker engine. Sensely's platform uses virtual avatars to support patient triage and navigate individuals through healthcare systems. The combination of Mediktor’s diagnostic accuracy with Sensely’s conversational interface enables health systems and insurers to deploy virtual assistants that direct patients to the appropriate level of care, helping to optimise resources and reduce clinical workloads. Venture to Venture M&A: Strategic Consolidation in European HealthTech and MedTech Strategic Implications for the Digital Health Value Chain The shift from independent point solutions to integrated platform models is reshaping value creation and competitive dynamics across the European healthcare ecosystem. Shifting from Fragmented Point Solutions to Platforms For enterprise buyers, managing multiple independent digital health applications has become commercially and technically challenging. Employers, commercial insurers and public health systems are increasingly prioritising integrated platforms over single purpose apps. Consolidating multiple clinical pathways under a single platform offers several strategic advantages: Interoperability and Data Architecture: Integrated platforms connect diagnostic, remote monitoring and triage tools under a unified data framework, reducing data silos. Regulatory Compliance and Security: Platforms with established regulatory infrastructures can absorb the high compliance overhead of GDPR, the EU AI Act and clinical device standards. Demonstrable Return on Investment: Unified platforms with integrated clinical dashboards allow enterprise buyers to measure patient outcomes and financial returns through a single vendor. Automated Administration and Margin Expansion Tuck-in acquisitions are also targeting automated provider operations and administrative workflows, which have become a significant focus for venture capital and private equity investment. This sub-sector captured approximately 44% of total healthtech funding, driven by the immediate returns of administrative automation. By integrating generative AI and large language models (LLMs) into billing, coding, and prior authorisation workflows, consolidators can automate routine clinical claims and documentation. This automation helps expand operational margins, in some cases shifting service heavy business models toward high-multiple, recurring software-as-a-service (SaaS) frameworks. This transition supports the broader maturation of the European healthtech and medtech sectors, helping to build sustainable, clinically validated platforms capable of addressing the rising costs and capacity constraints facing European health systems. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Digital Health IPO Landscape in 2026 and Exit Backlog Paradox Structural Re-engineering of the Healthtech Exit: The 2026–2027 Digital Health IPO Landscape and Valuation Reset The public equity market for digital health entered a period of pronounced stagnation in 2026, creating a stark paradox for the venture capital ecosystem. While broader healthcare sectors, biotechnology platforms and emergency service providers successfully accessed public capital, not a single core digital health platform completed an initial public offering (IPO) during the first half of the year. This freeze stands in sharp contrast to the momentum of Mid 2025, when a brief opening of the public window allowed five pioneering healthtech companies, Hinge Health, Omada Health, HeartFlow, Carlsmed, and Profusa to break a multi-year listing drought. The completed listings of 2025 proved that public markets would support scaled, operationally disciplined healthtech companies. For example, Hinge Health (NYSE: HNGE) priced its IPO at the top of its range at $32 per share, raising $437 Million at an implied valuation of $2.6 Billion. Omada Health (NASDAQ: OMDA) followed shortly after, completing its listing to raise $150 Million at a valuation of $1.1 Billion. Meanwhile, the precision oncology and clinical diagnostics developer Caris Life Sciences priced its IPO to list on NASDAQ as well. The year closed with the massive $6.26 Billion listing of medical supply giant Medline, confirming deep institutional demand for healthcare assets with predictable margins and immense scale. This momentum did not translate into active digital health IPOs in 2026. While early 2026 saw non-digital healthcare sectors thrive, evidenced by biotechnology companies pulling in over $1 Billion in a single week and emergency transport provider GMR Solutions raising $479 Million in its NYSE listing, the core digital health window remained closed. This ongoing stagnation has created a major backlog. Dozens of late stage digital health platforms that raised billions in venture funding at peak valuations must go public, as few strategic corporate buyers can afford to acquire them at their current scales. The resulting buildup of pre-IPO companies is forcing a structural revaluation across the private market. Quantitative Trends in Healthtech Private Capital Allocation The stagnation of the 2026 public exit window is directly impacting private market financing. Rather than a collapse in aggregate funding, the sector is experiencing a concentrated consolidation of capital. Private equity and late stage venture funds are executing fewer, larger transactions, focusing on enterprise grade software and platforms with defensible intellectual property. Metric 2021 2022 2023 2024 2025 Total U.S. Venture Capital Funding $29.3Bn $15.3Bn $10.7Bn $10.5Bn $14.2Bn Total Global Venture Capital Funding $52.7Bn $25.5Bn $13.2Bn $17.2Bn (US) $28.8Bn Deal Count (U.S.) 729 572 509 509 482 Average Deal Size (U.S.) $40.2M $26.8M $21.0M $20.7M $29.3M Concentration into Mega-Deals ($100M+) — — — — 42% of total AI Share of Sector Funding — 29% 33% ~45% 54% The funding patterns illustrate a transition from speculative, consumer directed models to enterprise platforms. While total deal counts in 2025 reached a five-year low of 482, the average deal size rebounded by 42% to $29.3 Million, driven by the concentration of capital into market-dominant platforms. This concentration of capital is highly focused on clinical AI, which captured 54% of all digital health funding in 2025. This trend is driven by clear return-on-investment parameters, with healthcare AI tools yielding an average payback period of 14 months and returning $3.20 for every $1.00 invested. As the 2026 public window remains closed, late-stage crossover investors, including Fidelity, T. Rowe Price, Coatue, and Wellington Management, are shifting their focus toward capital-preservation strategies, funding highly selective late-stage bridge rounds to sustain balance sheets until a viable public window opens in 2027. The Shift in Valuation Metrics: 2021 Peak vs. Modern Realities The public and private market valuation framework has undergone a major correction since the 2021 peak. The speculative multiples of the pandemic era, which frequently reached 15x to 20x forward revenues for growth-at-all-costs platforms, have been replaced by strict fundamentals. In the 2026 market, core digital health companies are valued within a normalised range of 4x to 6x revenue. Premium platforms that present proprietary AI, deep integration into medical clinical workflows and validated data moats command multiples of 6x to 8x+. Conversely, sub-scale or unprofitable companies without clinical evidence are compressed to multiples of 3x to 4x revenue. Public & Private Health Tech Cohort Enterprise Value to Revenue Multiple Annualized Revenue Growth Rate Free Cash Flow (FCF) Margin Rule of 40 Score (Growth + FCF) HeartFlow 13.8x 49% -36% 13% Tempus AI 9.3x 85% -22% 63% Caris Life Sciences 8.9x 117% -7% 110% Waystar 6.9x 12% 27% 39% Hinge Health 5.7x 72% 26% 98% Omada Health 2.5x 65% -1% 64% Healthtech Cohort Average 7.2x 67% -2% 65% The financial data of this cohort shows that the public markets continue to apply a discount to platforms that lack positive cash generation. Although modern healthtech companies exhibit growth and free cash flow margins that match or exceed those of top-tier cloud software companies, they trade at a 10% to 20% discount relative to their enterprise SaaS counterparts. This valuation discount is expected to close as AI-native digital health companies prove their structural leverage. Traditional medical services generate an average of $100,000 to $200,000 in revenue per full-time equivalent (FTE), and legacy healthcare SaaS generates $200,000 to $400,000 per FTE. However, AI-native platforms are achieving $500,000 to over $1 Million in revenue per FTE. This performance is driving a transition in investor evaluation from revenue-based screening to EBITDA-based metrics, with profitable mid-market digital health platforms commanding 10x to 14x EV/EBITDA. Digital Health IPO Landscape in 2026 and Exit Backlog Paradox Profile Analysis of the Private Backlog Waiting in the Wings The pool of digital health companies awaiting a public listing represents a diverse mix of technologies, scale, and operational focus. These companies can be categorised by their core technology engines and market strategies. Clinical Artificial Intelligence and Data Platforms Abridge has positioned itself as a leading clinical generative AI platform, focused on reducing clinician burnout by automating medical documentation and clinical conversation summaries. Now deployed across more than 150 health systems and analyzing over 50 million medical conversations annually, Abridge has demonstrated strong clinical workflow integration with enterprise partners like Johns Hopkins, Kaiser Permanente and the Mayo Clinic. Supported by a $300 million Series E round in mid-2025 that increased its valuation to $5.3 Billion, Abridge presents a highly predictable, SaaS-like recurring revenue model that is well-suited for a targeted public listing. Innovaccer, known as the "Healthcare Intelligence Cloud," provides a critical data integration layer that unifies fragmented patient records for large health systems. By maintaining a 50% year-over-year revenue growth rate for five consecutive years while generating positive cash flow, Innovaccer has established a stable financial foundation. A $75 Million secondary ESOP buyback in January 2026 provided liquidity to early employees and signalled structured financial preparation for an IPO. The company was valued at $3.45 Billion in its January 2025 funding round. Commure focuses on automated administrative workflows to reduce clinical and administrative overhead. Backed by a Series D-3 funding round of $70 Million in May 2026, led by General Catalyst and Sequoia Capital, Commure achieved a $7.0 Billion valuation, establishing a strong capital position for an eventually receptive public market. Wearables, Devices and Early Diagnostics Oura Health is transitioning from consumer wellness to clinical diagnostics. The company sold over 5.5 million smart rings by late 2025 and is projected to generate between $1.5 Billion and $2.0 Billion in revenue in 2026, up from $1.0 Billion in 2025. Supported by a late 2025 Series E round that valued the company at $11 Billion, Oura confidentially filed for an IPO in mid-2026, leveraging its high recurring subscription revenue and a cash-rich balance sheet. Freenome develops blood-based tests for early-stage cancer detection, utilising its multiomics platform to analyse cell-free biomarkers via machine learning. Freenome announced a definitive business combination with Perceptive Capital Solutions Corp, which is expected to yield $330 Million in gross proceeds and establish a post-merger equity value of approximately $1.1 Billion under the NASDAQ ticker "FRNM". Speciality Virtual Care and Metabolic Reversal Platforms Ro has transitioned from a direct-to-consumer telemedicine provider into a vertically integrated telehealth infrastructure platform. Sources indicate that Ro's revenue run rate grew from $185.3 Million in 2023 to $598 Million in 2024, with growth accelerating into 2026. By establishing direct-to-consumer integrations with pharmaceutical manufacturers like Novo Nordisk for GLP-1 weight loss therapies, Ro is positioning itself for a 2027 public listing. Ro was last valued in the private markets at $7.0 Billion in 2022. Noom has navigated the competitive GLP-1 prescribing market with its "Microdose" clinical program, which pairs low-dose compounded semaglutide with digital behavioural coaching. This combination accounts for 60% of Noom's revenue. Noom possesses zero debt, positive EBITDA, and positive free cash flow, and is re-evaluating the public markets after postponing its initial IPO plans in 2022. The company was valued at $3.7 Billion in its 2021 funding round. Virta Health utilises a specialised clinical model to reverse Type 2 diabetes and provide clinical oversight for patients tapering off GLP-1 medications. Surpassing $160 Million in annualised revenue in late 2025 with an 80% year-over-year growth rate, Virta Health is positioned as a key partner for payers seeking to manage metabolic drug spend. CEO Sami Inkinen has stated that the company expects to be IPO-ready in 2026. The company was valued at $2.0 Billion in 2021. Workforce Mental Health and Enterprise Benefits Navigation Lyra Health represents a major enterprise platform in employer-sponsored mental health care, covering 17 million lives and commanding approximately 18% to 22% of the premium U.S. workforce market. Lyra Health's annualised revenue run rate reached $235 Million in late 2024, up from $111.3 Million in 2023. The company is valued at $5.58 Billion to $5.9 Billion. Its proprietary network of over 10,000 clinicians allows Lyra Health to guarantee care access in 2.2 days, compared to the 25-day national average, supporting a strong enterprise ROI model. The company secured a $57 Million Series G funding round in June 2026 to fund its clinical AI integrations. Spring Health, another major employer-focused mental health platform, expanded its coverage to over 20 million lives. Spring Health has raised approximately $509 Million in venture capital, with its latest valuation at $3.3 Billion. The company explicitly signalled its public intentions following a $100 Million Series E round, designed to strengthen its balance sheet for an IPO. Maven Clinic is a large virtual provider of women's and family health services, serving over 2,000 employers and health plans. In 2025, Maven Clinic expanded its client base by 170%, covering 23 Million individuals globally. Valued at $1.7 Billion in its 2024 Series F round, the company appointed senior executives with public market experience in 2025, signalling deliberate preparations for an IPO. Devoted Health combines a Medicare Advantage plan with a virtual-first clinical group. Devoted Health has raised $2.3 Billion in capital, with its last valuation at $12.6 Billion. The company's technology enabled administrative model yields higher margins than traditional insurers, making it a strong value based candidate for 2026. Regional Regimes and Cross-Border Listing Venue Dynamics The structural environment of the 2026–2027 IPO market is heavily influenced by regulatory updates and listing platform dynamics across the United States and Europe. High-growth European digital health companies are increasingly restructuring via the "Delaware Flip" to list directly on the NASDAQ or NYSE, seeking to access deeper public capital pools and achieve valuation parity with U.S. competitors. In response to capital flight, European financial authorities have implemented regulatory updates to retain home grown healthcare champions: The UK Financial Conduct Authority (FCA): The FCA removed the historical requirement for shareholder votes on certain transaction classes and relaxed dual-class share restrictions to make the London Stock Exchange (LSE) more appealing to founder-led companies. This supports LSE candidates like Huma, which is positioned as "the AWS of digital health" with its clinically cleared hospital-at-home platform. Deutsche Boerse: The German exchange reduced post-IPO capital listing fees, while Germany’s Future Financing Act relaxed listing requirements and expanded opportunities for Special Purpose Acquisition Companies (SPACs). Euronext: Standardised cross-border listings using English documentation via the European Common Prospectus initiative, which was fully enacted in late 2024 to simplify listings for companies like France’s Doctolib. This regulatory environment is further shaped by strict compliance frameworks. The EU AI Act, enforced in March 2026, imposes strict data governance, transparency, and validation standards on medical AI algorithms designated as "high-risk". This has shifted venture capital away from "black box" machine learning models toward explainable AI solutions that can pass clinical audits, creating a compliance moat for established platforms. Additionally, the European Health Data Space (EHDS) mandates that clinical networks make electronic health data available for secondary research, turning secure clinical databases into valuable assets that support the valuations of platforms like Owkin and Huma. Systematic Implications of the Stagnant Exit Window on Healthcare Operations The lack of digital health IPO exits in 2026 has direct, practical consequences for telehealth buyers and healthcare practices. Because many late-stage virtual care and clinical platform vendors are unable to access public markets for liquidity, they are under pressure to extend their cash runways. This financial strain creates several operational risks for healthcare organisations evaluating multi-year technology contracts: Roadmap Stagnation: To conserve capital, late-stage vendors are frequently forced to implement hiring freezes, reduce staff, or suspend research and development budgets. This means the technology platform a medical practice selects in 2026 is highly likely to see its development roadmap frozen for 12 to 18 months, leaving the buyer anchored to a stagnant platform. Vendor Insolvency and Reinsurance Exposure: Rising interest rates and changes to Medicaid and Affordable Care Act (ACA) reimbursement structures are putting pressure on vendor balance sheets. If a critical virtual care or remote patient monitoring vendor experiences insolvency, it can disrupt patient care workflows and expose health systems to compliance risks. Defensive Consolidation: To survive, smaller virtual care providers are merging with larger, more stable platforms, often at compressed valuations (e.g., Swoop acquiring Nimble). While consolidation can bring stability, it often leads to product sunsetting, forced data migrations, and integration challenges for the clinical practices using those systems. Consequently, healthcare procurement offices in 2026 are shifting their evaluation criteria from purely technical features to balance sheet durability. Organisations must require prospective vendors to provide clear disclosure regarding their cash reserves, burn rates, and historical funding cycles before committing to long-term enterprise agreements. Strategic Imperatives for Late-Stage Exit Readiness To successfully list in the late 2026 or 2027 window, candidates in the digital health backlog must transition from venture-backed growth strategies to public-market discipline. This operational transition requires focusing on three key areas: SaaS-Equivalent Unit Economics: Candidates must show that their platform models can generate stable gross margins of 60% to 80%. This requires automating clinical documentation, improving automated routing, and utilising AI assistants to increase the revenue generated per clinician and administrative employee. Rule of 40 Validation: Public markets are applying a discount to digital health platforms that exhibit high growth but significant losses. Listing candidates must show a clear path to positive EBITDA, ensuring their growth rate combined with their free cash flow margin satisfies the "Rule of 40" threshold. Clinical Evidence and Regulatory Compliance: As regulatory guardrails like the EU AI Act and MDR/IVDR become fully enforced, public market investors are demanding clinical validation. Candidates must back their platforms with randomized controlled trials (RCTs), peer-reviewed real-world outcomes, and payer-grade cost-effectiveness data to justify premium valuations. By focusing on these operational fundamentals, the digital health candidates currently waiting in the wings can build the financial durability needed to navigate a selective public listing window and secure long-term public market support. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Structural Convergence of Care Management and Remote Monitoring: A Strategic Valuation of ChartSpan’s Acquisition of Validic On June 22nd, 2026, ChartSpan Medical Technologies finalised its strategic acquisition of Validic, a prominent personal health data and healthcare Internet of Things (IoT) platform. Operating as a consolidated entity under the ChartSpan banner, the transaction establishes a unified clinical delivery layer that merges full-service virtual care teams with a scaled device-logistics and data normalisation ecosystem. The transaction bridges a historically fragmented healthcare data gap by combining traditional Chronic Care Management (CCM) and Advanced Primary Care Management (APCM) with continuous, home-based Remote Patient Monitoring (RPM). Transaction Overview and Financial Underpinnings While the transaction’s absolute dollar valuation was not publicly disclosed, the acquisition was supported by structured institutional financing led by BIP Capital. The investment firm’s efforts were directed by Managing Partner and CEO Mark Buffington alongside Principal RT Wyatt. Securities and Exchange Commission (SEC) filings reveal that a specialised Delaware-incorporated entity named BIP Ventures ChartSpan Equity I-QP, LLC (CIK: 0002126958) was registered in 2026 to facilitate the capitalisation. The entity initiated a pooled investment offering of $15,100,000 on June 2, 2026, with $6,890,000 in equity sold as of mid-June 2026. To execute the transaction, Validic retained Oppenheimer & Co. Inc. as its exclusive financial advisor. Prior to the acquisition, both organisations maintained independent, highly capitalised trajectories. ChartSpan had accumulated $37.1 million across six funding rounds, notably anchored by a $15 million Series A round in June 2019 led by BIP Capital, which led to the appointment of BIP Capital's Sarath Degala to ChartSpan’s Board of Directors. Validic had secured $31.6 million across eight investment rounds, backed by institutional investors including Kaiser Permanente Ventures, SJF Ventures, and Greycroft. Capitalisation and Financial Parameters ChartSpan Medical Technologies Validic, Inc. Consolidated Organization Total Venture Funding Raised $37.1 Million $31.6 Million Structured consolidated debt & equity capital Primary Institutional Backers BIP Capital, Blue Heron Capital, Cypress Growth Capital Kaiser Permanente Ventures, SJF Ventures, Greycroft BIP Capital, BIP Ventures, and historic investors Lead Investment Advisors Croft & Bender (historic) Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. and BIP Capital Transaction Structure Corporate Acquirer Acquired Subsidiary Merged operating unit under ChartSpan brand Historical Trajectories and Strategic Positioning ChartSpan was co-founded in 2012 by Jon-Michial Carter, his brother, and a third unnamed co-founder in Greenville, South Carolina. The startup emerged from The Iron Yard accelerator, initially focusing on a patient-facing mobile application designed to digitize paper-based medical charts through mobile optical character recognition. Recognizing structural shifts in federal reimbursement, ChartSpan pivoted to become the largest provider of managed Chronic Care Management services in the United States. Under the executive leadership of Chief Executive Officer Christine Hawkins, the company deployed specialised clinical software and an expansive, 24/7 virtual nursing workforce to manage high-risk Medicare populations. ChartSpan achieved strong performance metrics, including average patient enrollment rates of 45% in primary care practices and 35% in specialty practices, supported by complimentary Merit-based Incentive Payment System (MIPS) and quality improvement services for its clients. Validic was founded in 2010 by Drew Schiller and Ryan Beckland in Durham, North Carolina, as a pioneer in patient-generated health data aggregation. Operating as a platform-as-a-service (PaaS) model, Validic’s core database normalized and integrated biomedical telemetry from hundreds of disparate clinical and consumer devices. By 2026, the company’s platform reached over 223 million lives across 52 countries. A major turning point in Validic's operational history occurred on May 15th, 2023, when the company acquired the assets of Trapollo LLC, a connected health and device logistics provider, from its parent company, Cox Communications. This acquisition integrated Trapollo's fulfillment center in Sterling, Virginia, directly into Validic's operations. Steve Nester, the former General Manager of Trapollo, transitioned to Senior Vice President and General Manager of Validic’s logistics division. The integration of Trapollo enabled Validic to manage the entire device lifecycle, including inventory management, configuration, delivery of pre-paired medical kits, and patient technical onboarding. This operational capability was demonstrated in its joint program with Kaiser Permanente on the West Coast, which supported over 300,000 enrolled patients. This scale of clinical and device logistics integration yielded documented, high-precision clinical outcomes across large populations. Clinical & Operational Metrics Kaiser Permanente & Joint Program Baseline Outcomes Enrolled Population (West Coast) 300,000+ patients since program inception Glycated Hemoglobin (A1C) Control 1.2 point absolute reduction within a 90-day period for diabetic patients Systolic Blood Pressure (SBP) Control 12% drop in SBP in 45 days, transitioning stage 2 hypertension to normal Clinical Efficiency Rate 88% of participating clinicians reported saved administrative and active clinical time Clinician-Patient Communication 63% reduction in phone call times, from an average of 15 minutes to 5.5 minutes Patient Adherence and Engagement 76% of enrolled patients maintained biometric readings at least twice daily after 90 days Patient Care Satisfaction Score 75% of active participants reported feeling they were receiving superior, highly personal care Technical Integration and Product Infrastructure The combined platform combines Validic's two primary product categories, Validic Inform and Validic Impact, directly with ChartSpan’s care orchestration workflows. Validic Inform acts as a persistent, standardised data infrastructure layer. Rather than requiring hospital IT teams to build separate API integrations for different medical hardware brands, the Inform platform normalises streams from over 700 consumer and clinical-grade devices into a unified, developer-friendly interface. The system operates across a wide array of technical interfaces, providing developers with REST APIs, real-time streaming services, native iOS and Android SDKs, and push notification architectures. Validic Impact builds upon this normalization engine to deliver a turnkey, clinical-facing application integrated directly into electronic health records (EHRs) such as Epic and Oracle Health (Cerner). By writing biometric data directly to EHR flowsheets, clinical charts, and in-basket routing systems, the platform minimizes the administrative burden on clinical staff. When combined with ChartSpan’s human capital, this integration changes the delivery of remote care. Instead of practicing blind, periodic monthly outreach, ChartSpan’s care managers can review continuous physiological data and respond to automatic alerts triggered by patient devices. This continuous clinical triage allows care teams to address physiological decompensation in real time, preventing conditions from worsening into emergencies. Regulatory Compliance and Reimbursement Economics under CMS Guideline Revisions The financial and operational rationale for combining CCM, APCM, and RPM services is reinforced by updates in the Medicare Physician Fee Schedule (PFS). Historically, primary care groups struggled with the administrative burden of tracking staff minutes for Chronic Care Management billing. To address this friction, CMS introduced Advanced Primary Care Management (APCM) on January 1st, 2025, as an activity-based monthly bundle comprising 13 structural service elements. APCM consolidates the care coordination goals of CCM, Principal Care Management (PCM), and Transitional Care Management (TCM) into a single, non-time-based billing structure. In the CY 2026 Physician Fee Schedule, CMS increased reimbursement rates by approximately 10% across the three base APCM G-codes (G0556, G0557, G0558). In addition, CMS finalised three new behavioral health integration (BHI) add-on codes, G0568, G0569, and G0570, designed to support the Psychiatric Collaborative Care Model (CoCM) and general BHI within primary care workflows without requiring time-based documentation. Rural Health Clinics (RHCs) and Federally Qualified Health Centers (FQHCs) have also transitioned to these codes, billing individual APCM codes at national non-facility PFS rates. HCPCS Billing Code Risk & Complexity Level Qualifying Patient Profile 2025 National Rate 2026 National Rate Key Reimbursement Guidelines G0556 Level 1 APCM Patients diagnosed with 0 to 1 chronic condition. $15.00 ~$16.00 Requires verbal/written patient consent; primary care provider only. G0557 Level 2 APCM Patients diagnosed with $\ge 2$ complex chronic conditions. $49.00 ~$54.00 Conditions must last $\ge 12$ months, posing significant risk of acute decline. G0558 Level 3 APCM Level 2 clinical criteria + Qualified Medicare Beneficiary (QMB) status. $107.00 ~$117.00 Intended for dual-eligible populations with state-covered copays. G0568 CoCM Add-on Initial month of Collaborative Care Model services. N/A ~$162.00 Billed alongside base APCM codes; mirrors CPT 99492 but without time tracking. G0569 CoCM Add-on Subsequent months of Collaborative Care Model services. N/A ~$146.00 Billed alongside base APCM codes; mirrors CPT 99493 but without time tracking. G0570 General BHI Add-on Continuous general Behavioral Health Integration. N/A ~$57.00 Billed alongside base APCM codes; mirrors CPT 99484 but without time tracking. Under CMS regulations, APCM and traditional CCM codes are mutually exclusive for the same patient in the same billing month. However, providers are explicitly permitted to bill either APCM or CCM concurrently with Remote Patient Monitoring (RPM). To bill both services concurrently and maintain compliance during audits, clinical teams must adhere to strict guidelines. First, both programs must independently satisfy their respective CMS criteria. No clinical activity minutes may be double-counted; the time a care team spends coordinating chronic care (CCM) cannot be counted toward the time a clinician spends reviewing physiological data (RPM). For new patients, an initiating face-to-face visit, such as an Annual Wellness Visit (AWV) or standard Evaluation and Management (E/M) service, is required to discuss and obtain separate consent for each program. The RPM component requires the patient to use an FDA-defined medical device that automatically transmits physiological measurements, recording a minimum of 16 days of readings in a 30-day period (CPT 99454). Additionally, the care team must spend a distinct 20 minutes per month performing clinical data review and interactive communication (CPT 99457). The Structural Convergence of Care Management and Remote Monitoring: A Strategic Valuation of ChartSpan’s Acquisition of Validic Market Expansion and Enterprise Commercial Strategy The acquisition of Validic transforms ChartSpan’s commercial model from a clinic-focused care provider into a multi-sided enterprise digital health platform. Traditionally, ChartSpan’s client footprint was concentrated in independent primary care practices. By integrating Validic’s assets, the combined organisation can expand its commercial target footprint to serve health systems, commercial payers, digital health innovators and life sciences companies. For health systems and Accountable Care Organizations (ACOs), the consolidated platform addresses the operational fragmentation caused by managing multiple digital health point-solutions. Instead of using separate vendors for care management, remote patient monitoring devices, patient onboarding and EHR software integration, health systems can deploy ChartSpan as a single, unified clinical and technological partner. This approach simplifies procurement, aligns clinical care teams, and lowers administrative overhead for hospital staff. For payers and managed care organisations, the combined offering supports proactive risk management. By using home-based biometric telemetry, payers can identify physiological decompensation early and intervene before conditions worsen, helping to reduce expensive emergency room visits and hospital readmissions. For digital health innovators and life sciences companies, the platform provides a scalable data infrastructure. Access to normalised real-world data (RWD) from over 20 Million connected lives can help life sciences organisations track long-term treatment efficacy, monitor medication adherence, and streamline decentralised clinical trial designs. Strategic Implications and Future Outlook The consolidation of ChartSpan and Validic represents a significant maturity milestone for the remote care industry. For over a decade, the health IT market operated in silos, with software vendors providing data connectivity and clinical organizations operating in isolation. This transaction directly addresses that fragmentation by combining a scaled health IoT platform and device logistics system with a dedicated clinical care workforce. As CMS continues to transition toward value-based reimbursement models, such as Advanced Primary Care Management, the demand for integrated, continuous remote care is expected to rise. By leveraging its in-house device logistics, real-time data normalization, and 24/7 virtual care teams, the combined entity is well-positioned to lead this shift. This unified approach helps healthcare organizations move beyond periodic, episodic patient observations to establish a model of continuous clinical understanding. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The MedTech and HealthTech Corporate Divestiture landscape over the next 12 months The global medical technology and healthcare technology sectors are undergoing a profound structural realignment, shifting from post-pandemic volume driven consolidation toward highly disciplined portfolio design. Corporate divestitures, spin-offs and carve-outs have become primary mechanisms for multinational healthtech organisations seeking to optimise operating margins, reduce debt and redeploy capital toward high-growth, high-margin clinical categories. Driven by macroeconomic volatility, persistent inflation, supply chain pressures and localised market headwinds, corporate boards are abandoning broad diversification in favour of absolute category leadership. This corporate rationalisation is further accelerated by operational challenges in key markets such as China, alongside shifts in clinical care delivery, particularly the rapid migration of procedures to ambulatory surgical centres (ASCs) and home-care environments. Consequently, corporate assets that fail to align with a parent company's core operating model, clinical sales channels, or capital expenditure requirements are actively being carved out. Over the next 12 months, this structural pivot will produce a deep pipeline of high-value carve-out opportunities for both strategic acquirers and private equity investors. The New Paradigm of Portfolio Discipline and Strategic Consolidation The broader medtech mergers and acquisitions landscape demonstrates a clear rebound in aggregate transaction values, contrasted by a decline in overall deal participation. This divergence indicates a highly selective environment where capital is concentrated in fewer, larger, and more strategic transactions. Aggregate announced medtech deal values surged to approximately $61 Billion in 2025, up from $45 Billion in 2024 and $26 Billion in 2023. This momentum has carried into 2026, with the first half of the year generating $36.5 Billion in transaction value, including a robust Q1 that recorded approximately $27 Billion across 38 deals. This consolidation is characterised by massive strategic platforms, illustrated by Boston Scientific's $14.5 Billion acquisition of thrombectomy leader Penumbra in January 2026 and Danaher Corporation's $9.9 Billion acquisition of Masimo Corporation in February 2026. Together, these two transactions represented approximately 94% of total Q1 2026 deal value, highlighting a market that heavily favours established, operationally mature targets with proven scalability. Concurrently, spin-offs and divestitures accounted for approximately 34% of total medtech deal value in 2025, a noticeable increase from the five-year historical average of 29%. This acceleration reflects a fundamental shift in corporate strategy. Large multinationals are actively pruning non-core operations to unlock shareholder value and defend operating margins. Recent landmark divestitures, such as Solventum's $4.1 Billion sale of its Purification & Filtration business to Thermo Fisher Scientific and Baxter International's $3.8 Billion sale of its Vantive kidney care unit to the Carlyle Group, demonstrate how corporate spin-offs are rapidly followed by secondary portfolio rationalisation. Major Medtech Divisional Divestitures and Structural Separations (2025–2026) Divesting Parent Target Business Unit / Division Transaction Value & Structure Buyer / Transaction Partner Operational Status / Close Date Becton Dickinson Biosciences & Diagnostic Solutions $17.5 Billion; Reverse Morris Trust Waters Corporation Completed February 9, 2026 Solventum Purification & Filtration $4.1 Billion; Direct Asset Sale Thermo Fisher Scientific Completed Baxter International Vantive Kidney Care $3.8 Billion; Direct Asset Sale Carlyle Group & Atmas Health Completed January 2025 Royal Philips Emergency Care Undisclosed Value; Brand Licensing Bridgefield Capital Completed January 8, 2026 Medtronic Patient Monitoring & Recovery (Partial) $6.1 Billion; Cash Asset Sale Cardinal Health Completed This ongoing rationalisation suggests that corporate diversification is being systematically deprioritised in favor of market-specific depth. Companies are increasingly evaluating where they possess a differentiated "right to win," shedding auxiliary businesses to concentrate financial and human capital on high-margin, clinically urgent spaces. Active Divisional Carve-Outs and Structured Separations The corporate carve-out pipeline for the next 12 months is anchored by several multi-billion-dollar divisions currently undergoing active financial and operational separation. These assets are transitioning from integrated corporate units into independent, market-ready targets. Siemens Healthineers: The Diagnostics Carve-Out The most significant structural separation in the active pipeline is the formal carve-out of the Diagnostics business unit by Siemens Healthineers. In May 2026, corporate management officially transitioned the Diagnostics separation from an exploratory assessment to an active, group-wide operational carve-out project. This decision was driven by sharp operational divergence between the company's high-performing imaging and advanced therapies segments and its underperforming diagnostics division. The Diagnostics business has faced severe headwind in the Chinese market, which accounts for approximately 10% of total Siemens Healthineers revenue, due to the domestic implementation of volume-based procurement policies and centralised reimbursement cuts. This pricing pressure led to a 6.5% year-over-year decline in Diagnostics revenue, dragging down consolidated corporate performance and prompting management to lower its fiscal 2026 revenue growth guidance to 4.5%–5.0% and compress its adjusted basic earnings per share outlook to €2.20–€2.30. The Diagnostics carve-out is structured to establish absolute strategic optionality. By decoupling the Diagnostics business from the highly profitable Imaging and Precision Therapy divisions, Siemens Healthineers creates a clean asset prepared for a potential trade sale, a joint venture, or a private equity buyout. This operational separation runs parallel to a broader corporate event: parent company Siemens AG is preparing to deconsolidate its remaining 67% controlling stake in Siemens Healthineers. Siemens AG plans to execute a direct spin-off of a 30% stake in Siemens Healthineers to its own shareholders in early 2027, with formal shareholder votes scheduled for February 2027. Carving out the volatile Diagnostics segment maximises the market value and financial profile of the core Siemens Healthineers imaging business prior to this parent-level unwind. Johnson & Johnson: The DePuy Synthes Strategic Unwind Johnson & Johnson is actively preparing for a major portfolio rationalization through the potential sale or structured carve-out of its orthopedics subsidiary, DePuy Synthes, in a transaction estimated to exceed $20 billion. DePuy Synthes is a major force in the global orthopaedic market, producing hip, knee, trauma, and spine implants that generated approximately $9.3 billion in revenue in 2025 and maintained a 6.3% growth rate in the first quarter of 2026. Despite its scale, the orthopedics division represents a mature, capital-intensive segment characterized by heavy clinical sales overhead and pricing compression. Johnson & Johnson's overarching strategy is to shift capital and operational focus entirely toward its highest-growth, highest-margin segments, specifically Innovative Medicine and its advanced interventional MedTech solutions in surgery, vision, and cardiovascular care. While J&J originally evaluated a tax-free public spin-off as the primary separation path, the company has pivoted to compile comprehensive carve-out financials to facilitate a direct sale. Large-cap private equity consortiums have emerged as the most likely buyers, though interest from rival medtech strategics remains possible. To prepare the asset for separation, DePuy Synthes has continued to execute localized acquisitions, such as its May 2026 purchase of the Gemtrack miniature radiofrequency tracking technology from MinMaxMedical. This technology integrates real-time tracking directly into DePuy's Velys digital surgery platform without relying on invasive pins or infrared line-of-sight cameras. By embedding high-value digital navigation capabilities directly into the joints portfolio, J&J is enhancing the clinical differentiation and valuation of the DePuy asset ahead of a finalised transaction. Becton Dickinson: The Biosciences & Diagnostics Separation The corporate separation of Becton Dickinson's (BD) Biosciences & Diagnostic Solutions business represents a completed blueprint for high-value structured carve-outs. Structured as a tax-free Reverse Morris Trust, the unit was spun off to BD shareholders and simultaneously combined with Waters Corporation in a transaction valued at $17.5 Billion. The transaction closed on February 9, 2026, following a record date set for February 5, 2026. Under the terms of the transaction, BD received a tax-free cash distribution of $4 Billion, which the company has committed to deploying toward debt reduction and share repurchases. BD shareholders received common stock in Waters Corporation, representing a 39.2% ownership stake in the combined entity. The resulting business combined Waters' expertise in liquid chromatography-mass spectrometry (LC-MS) and chemistry consumables with BD's diagnostic reagents, flow cytometry platforms and clinical regulatory footprint. The transaction was underpinned by highly complementary operational synergies, with the combined entity projected to realise $200 Million in annual cost synergies by year three and $290 Million in annual revenue synergies by year five. This separation allowed BD to focus on its medical and interventional segments while capturing significant equity upside in a pure-play life sciences and diagnostics leader. The Next Wave of 12-Month Strategic Divestitures (H2 2026–H1 2027) A secondary wave of corporate carve-outs is poised to enter the market over the next 12 months, driven by active parent restructuring, integration cleanup from recent mega-mergers, and regional risk mitigation strategies. Medtronic: The Complete Diabetes Spin-Off and Acute Care Focus Medtronic is actively pursuing a long-term strategy to streamline its diversified portfolio and concentrate capital on high-growth, high-margin opportunities. The primary target for complete separation in the next 12 months is its global Diabetes business unit. The Diabetes division, while commercially scaled, has faced intense competitive pressure in the continuous glucose monitoring (CGM) and insulin pump markets, which has limited its market share expansion. In fiscal year 2025, the Diabetes segment accounted for 8% of Medtronic's consolidated revenues, but contributed only 4% of total operating profits. To optimise its consolidated margin profile, Medtronic executed a carve-out IPO of its diabetes business under the MiniMed Group brand in Q1 2026, raising approximately $560 Million at a market capitalisation of $5.6 Billion. Medtronic plans to execute a complete split and divestiture of the remaining business by the end of 2026. This separation follows a historical precedent of portfolio pruning at Medtronic, including the prior $6.1 billion cash sale of a portion of its Patient Monitoring & Recovery division to Cardinal Health and its renal care joint venture with DaVita. Furthermore, Medtronic has restructured its remaining Patient Monitoring and Respiratory Interventions divisions. After canceling a planned standalone spin-off of these units in early 2024 due to shifting capital market conditions, the company combined them into a new Acute Care & Monitoring (ACM) segment. As part of this consolidation, Medtronic initiated a phase-out of its unprofitable ventilator product lines. Sub-acute patient monitoring lines within the ACM division remain highly susceptible to secondary private equity-backed carve-outs over the next 12 months as Medtronic focuses capital on its core cardiovascular, robotic surgery, and neurovascular segments. This is demonstrated by its $550 million acquisition of Scientia Vascular to expand its neurovascular footprint. Danaher Corporation: The Post-Acquisition Masimo Consumer Carve-Out Danaher completed its $9.9 Billion acquisition of Masimo Corporation on June 10, 2026, integrating Masimo’s clinical pulse oximetry, brain monitoring, and acute-care automation solutions into its Diagnostics segment. The acquisition was highly strategic, expanding Danaher's diagnostics franchise alongside established operating companies such as Beckman Coulter, Radiometer, Leica Biosystems and Cepheid. However, the final terms of the transaction required Danaher to absorb Masimo’s consumer audio and consumer health divisions, which were previously under review for a potential spin-off. Historically, Masimo’s acquisition of consumer audio parent Sound United for $1 Billion in 2022 triggered intense shareholder opposition and a proxy battle led by Politan Capital. While Masimo successfully sold Sound United to Samsung’s Harman division for $350 Million in May 2025, the remaining consumer health wearables and retail monitoring operations do not align with Danaher's business-to-business clinical model. Danaher operates with a strict focus on highly regulated, high-margin diagnostic platforms characterised by recurring consumable revenue streams. Consequently, Masimo’s non-clinical consumer health and retail-oriented pulse oximetry watch divisions are prime candidates for a strategic carve-out or private equity divestiture in late 2026 or early 2027 to pay down the commercial paper issued to fund the acquisition. GE HealthCare: Targeted Localisation and Regional Carve-Outs Since its independent spin-off from General Electric in 2023, GE HealthCare has focused on a software-enabled precision care model. In April 2026, the company executed a major segment restructuring, combining its two largest imaging divisions into a unified imaging and clinical visualization segment. This operational reorganization is designed to support its cloud-first enterprise imaging strategy, which was accelerated by the $2.3 Billion acquisition of Intelerad in March 2026. To protect global operating margins from regional macroeconomic pressures and domestic procurement policies, GE HealthCare is pursuing highly targeted localization strategies. In January 2026, the company commenced pre-marketing activities for a carve-out sale of its localized China imaging business. By selling a majority stake in this regional operation to domestic Chinese entities or localized joint ventures, GE HealthCare can insulate its global corporate margins from volume-based pricing compression in China. This structure allows the company to retain key manufacturing partnerships and licensing agreements while transferring capital-intensive local commercial operations off its consolidated balance sheet. Royal Philips: Refining the Connected Care Portfolio Royal Philips continues to execute its multi-year strategy to simplify its operational structure and concentrate resources on clinical imaging, ultrasound, and image-guided therapy. Following the completion of the sale of its Emergency Care business to Bridgefield Capital on January 8th, 2026, a transaction that included a 15 year brand licensing agreement, the company is evaluating further separations. The company's Connected Care segment, which includes patient monitoring and sleep and respiratory care products under the Respironics brand, has faced persistent regulatory and operational headwinds. Over the next 12 months, selective carve-outs of specific sub-acute respiratory care and home-use sleep therapy product lines are highly likely. This rationalisation will enable Philips to focus capital on high-margin hospital enterprise informatics, clinical AI integrations, and coronary intravascular imaging platforms, such as its recent acquisition of SpectraWAVE. The MedTech and HealthTech Corporate Divestiture landscape over the next 12 months Market Dynamics, Clinical Shifts and Valuation Adjustments The surge in medtech carve-out activity is fundamentally linked to shifts in clinical care delivery, technological requirements, and capital market valuation resets. Forward-Looking Pipeline of High-Probability Carve-Outs and Divestitures (H2 2026–H1 2027) Parent Corporation Target Divestiture / Carve-Out Unit Estimated Valuation Range Primary Structural Pathway Target Market / Clinical Category Strategic Rationale Siemens Healthineers Clinical Diagnostics Business $8.0 Billion – $12.0 Billion Group-wide formal carve-out; Trade sale or PE JV In-Vitro Diagnostics & Core Lab Testing Mitigate China procurement headwinds; optimize imaging core Johnson & Johnson DePuy Synthes $20.0 Billion+ Direct trade sale or Private Equity buyout Hip, Knee, Spine, and Trauma Orthopedics Capital reallocation to innovative oncology and immunology Medtronic Diabetes Division (MiniMed) $5.0 Billion – $6.0 Billion Complete corporate split and share distribution Insulin Pumps & CGM Systems Enhance margins; improve agility against pure-play competitors Danaher Corporation Masimo Consumer Health $400 Million – $600 Million Secondary carve-out; Private trade sale Wearable sensors & consumer monitoring Focus on B2B clinical diagnostics; debt reduction GE HealthCare Localized China Imaging Business TBD Pre-marketing regional carve-out Regional CT, MRI, and Ultrasound Insulate global margins from local pricing pressures Royal Philips Connected Care / Sleep Therapy lines $800 Million – $1.2 Billion Selective carve-out or private asset sale Home CPAP and Respiratory Consumables Portfolio simplification; focus on enterprise informatics The migration of high-acuity surgical procedures from traditional acute-care hospital settings to lower-cost, high-throughput ambulatory surgery centers (ASCs) is a primary operational catalyst. The Centers for Medicare and Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System and ASC Payment System final rule added more than 500 procedures to the ASC Covered Procedures List, including AFib-treating cardiac catheter ablations, advanced spine procedures, and complex cardiology interventions. This regulatory shift has altered the commercial landscape. Heavy, capital-intensive hardware platforms designed exclusively for stationary hospital operating rooms are experiencing declining commercial demand, making them key targets for corporate divestiture. Conversely, procedural platforms that are mobile, digitally integrated, and optimised for rapid clinical throughput are commanding high valuation premiums. Furthermore, the rise of GLP-1 receptor agonist therapies is reshaping strategic planning across the medtech sector. These metabolic therapies have the potential to reduce long-term device utilisation across obesity-linked therapeutic segments, including sleep apnea, diabetes management, joint reconstruction, and cardiovascular support. In response, strategic buyers are focusing their acquisition pipelines on clinical assets that remain insulated from or complementary to GLP-1 treatment pathways. This is illustrated by Stryker's acquisition of Inari Medical, which anchors portfolio growth in late-stage thromboembolic disease that persists downstream of metabolic dysfunction. Consequently, legacy device lines that are highly vulnerable to GLP-1-driven demand declines are being systematically deprioritized and prepared for divestiture. To bridge valuation gaps in an environment characterized by elevated capital costs and selective buyers, deal structures have evolved. Upfront cash considerations are frequently supplemented by earnouts, structured equity components, and performance-based milestone payments. These milestone payments are tied to specific clinical, regulatory, or commercial achievements, allowing sellers to capture fair value while mitigating integration risks for strategic and private equity buyers. Strategic Conclusions - MedTech and HealthTech Corporate Divestiture in the next 12 months The medtech and healthtech corporate divestiture landscape over the next 12 months is defined by a rigorous focus on core business optimisation and structural efficiency. Corporate leaders are increasingly utilising carve-outs to simplify governance, reduce operational complexity and insulate corporate balance sheets from inflationary and geopolitical headwinds. The active separation of Siemens Healthineers' diagnostics division, the potential sale of Johnson & Johnson's DePuy Synthes unit, and the ongoing spin-off of Medtronic's diabetes segment highlight a clear industry trend. These transactions demonstrate a shift away from the diversified healthcare conglomerate model in favour of agile, pure-play market leaders. For private equity sponsors and strategic buyers, these corporate separations provide a valuable pipeline of scaled, operationally mature assets with stable cash flows and established commercial channels. Acquirers who can successfully navigate the complexities of transitional services agreements (TSAs) and implement targeted operational improvements will be well-positioned to drive substantial value creation in a reorganising global healthcare market. Concurrently, divesting parent corporations will emerge as more focused, agile, and high-margin entities, with the capital flexibility required to invest in next-generation digital, robotic, and precision care platforms. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Engineering Sovereign AI in Healthcare: Architecture, Compliance, and National Strategies for On-Premises Clinical Deployment The Paradigm of Sovereign Infrastructure in Clinical Environments Clinical enterprises are undergoing a fundamental transformation in how they deploy, orchestrate and manage artificial intelligence workloads. The rapid integration of high-performance models into core workflows, ranging from real-time diagnostic imaging to predictive patient risk modelling and automated clinical documentation, has exposed the limits of traditional public cloud architectures. In response, healthcare systems are increasingly adopting sovereign artificial intelligence architectures. Sovereign AI represents a model-hosting paradigm in which a healthcare system runs its own AI platform on its own infrastructure, on-premises or in a dedicated single-tenant environment, ensuring that protected health information (PHI) never leaves its perimeter. This approach represents a shift from data residency to true technological and jurisdictional autonomy. While traditional AI deployments prioritise rapid scaling, convenience, and low initial infrastructure costs by utilising shared external cloud resources, sovereign AI focuses on complete control, systemic resilience and alignment with strict legal perimeters. It is critical to distinguish sovereign AI from simple data sovereignty. Data sovereignty focuses narrowly on the geographic location where raw data is stored and the legal framework governing that storage. Sovereign AI encompasses a broader ecosystem, asserting verifiable ownership over the entire AI technology stack. This includes the physical graphics processing units (GPUs) and server nodes, the model weights and training methodologies, the data processing pipelines, the execution runtime and the operational governance policies. AI sovereignty describes an organisation's high-level capability to control its artificial intelligence ecosystem, whereas sovereign AI provides the concrete technical infrastructure and computational foundation required to realise that control. Architectural Domain Traditional Cloud AI Deployment On-Premises Sovereign AI Architecture Physical Infrastructure Multi-tenant public cloud datacenters operated by foreign hyperscalers On-premises data centers or isolated single-tenant virtual datacenters Data Perimeter Controls Cryptographic transit across external network boundaries to third-party endpoints Zero-egress local perimeters; raw protected health information remains within the local network Legal & Jurisdictional Scope Subject to foreign extraterritorial laws and parent company disclosures Exclusive governance by regional legislation and local health authorities Execution Architecture Shared, multi-tenant container runtimes and remote API-based endpoints Isolated physical clusters, private containers, and local hardware enclaves Operational Autonomy Vulnerable to external internet outages, API deprecation, and remote shutdowns Air-gapped capable; continuous operations independent of public internet access Compliance Proofs Contractual agreements, standard security certificates, and third-party DPAs Hardware-enforced cryptographic attestations and local audit ledgers This architectural transition is driven by the reality that clinical datasets represent highly sensitive corporate intellectual property and high-value targets for cyberattacks. By bringing the model directly to the data rather than exporting data to external models, clinical enterprises can eliminate the risk of data leakage during transit, prevent the unauthorised use of clinical data for model training and protect their workflows against external operational disruptions. Regulatory and Jurisdictional Drivers: The Extraterritoriality Threat The regulatory environment governing healthcare operations globally has made the use of traditional multi-tenant cloud services increasingly complex and risky. In the United States, HIPAA mandates strict administrative, physical, and technical safeguards to protect patient health information, with clinical data breaches reaching an average cost of $9.77 Million dollars in 2024. In the European Union, GDPR Article 9 imposes a strict prohibition on processing "Special Category Data," which includes genetic, biometric, and health-specific information, unless explicit consent is obtained or a specific legal basis is established. Standard cloud service agreements and general Data Processing Agreements (DPAs) frequently fail to satisfy these Article 9 requirements, leaving healthcare institutions exposed to regulatory penalties that can reach up to 4% of global annual revenue. A major operational challenge for health systems is the legal reach of non-European extraterritorial laws over global cloud providers. Under the United States Clarifying Lawful Overseas Use of Data (CLOUD) Act and Section 702 of the Foreign Intelligence Surveillance Act (FISA), U.S. law enforcement and intelligence agencies can legally compel technology providers subject to U.S. jurisdiction to surrender data under their control, regardless of whether that data is physically stored in Europe, Dublin, or Frankfurt. This jurisdictional conflict was highlighted by the Court of Justice of the European Union in the landmark Schrems II ruling, which invalidated the EU-U.S. Privacy Shield framework. The court determined that standard contractual clauses and data residency promises cannot guarantee protection against foreign intelligence collection, even when data is hosted on European soil by subsidiaries of U.S. firms. This vulnerability was confirmed under oath during a French Senate inquiry, where Microsoft's legal director acknowledged that the company could not refuse a U.S. legal order seeking access to European citizens' data. To address these vulnerabilities, national cybersecurity authorities have developed rigorous certification standards to isolate sensitive operations from foreign legal jurisdictions. In France, the National Agency for Information Systems Security (ANSSI) developed the SecNumCloud qualification. Now in version 3.2, SecNumCloud enforces strict operational, legal, and organizational requirements. To achieve SecNumCloud qualification, a cloud offering must be hosted on physical infrastructure located exclusively within the European Union, administered by EU-based personnel, and operated by an entity whose capital structure and governance prevent any non-European parent organisation or shareholder from exercising direct or indirect control. By establishing a legal barrier against extraterritorial warrants, these qualified platforms ensure that sensitive databases are subject only to local judicial authorisation. National System Realignment: Case Studies in Clinical Autonomy France: The Health Data Hub Transition France’s shift toward digital sovereignty is illustrated by the decision to migrate its Plateforme des Données de Santé, commonly known as the Health Data Hub, off Microsoft Azure. The Health Data Hub was created to centralise and standardise health records across the French medical system, including the extensive Système National des Données de Santé (SNDS) database, to accelerate public health research, epidemiology and clinical AI development. Despite operating under strict security protocols, the platform faced continuous legal challenges and criticism from the CNIL, which refused to approve the permanent hosting of the full national dataset on Microsoft's cloud infrastructure due to potential exposure to U.S. intelligence laws. To resolve this issue, the French government launched a public procurement process tied to the UGAP framework, requiring that the future host be SecNumCloud-qualified. Following a competitive evaluation based on over 350 technical criteria, domestic cloud provider Scaleway was selected to replace Microsoft Azure. The transition is scheduled for completion between late 2026 and early 2027. This move highlights how digital sovereignty has transitioned from a theoretical policy goal into a mandatory procurement requirement for clinical workloads. United Kingdom: NHS Cyber Resilience and the Maturity Paradox In the United Kingdom, the operational vulnerability of clinical networks was highlighted in June 2024 by a ransomware attack on pathology supplier Synnovis. The attack disrupted services across multiple London hospitals, leading to the cancellation of thousands of operations, the postponement of critical appointments, and at least one patient death alongside over 120 documented cases of patient harm. This incident exposed the vulnerability of a highly connected digital network where a security compromise at a single node can disrupt services across multiple regional trusts. Digital health leaders, such as Humber Teaching NHS Foundation Trust CIO Lee Rickles, have emphasised that failing to manage infrastructure sovereignty presents a severe strategic risk. Clinical organisations face a "maturity paradox" where rapid digital adoption creates operational dependencies without a corresponding maturity in cybersecurity and system recovery capabilities. Furthermore, the Tony Blair Institute for Global Change and government advisory bodies have outlined a three-tiered AI infrastructure strategy designed to protect sensitive datasets while supporting local control. National Initiative Lead Agency / Sponsor Primary Objective Key Technical Architecture French Health Data Hub Migration Ministry of Health, ANSSI, CNIL Protect national clinical databases (SNDS) from foreign extraterritorial access SecNumCloud-qualified, HDS-certified Scaleway infrastructure UK AI Growth Zones (AIGZs) Department for Science, Innovation and Technology Cluster domestic compute power, streamline planning, and coordinate energy assets Corridor deployments (e.g., Slough to Cardiff) utilising experimental silicon UK Sovereign Venture Fund British State Venture Fund Capitalize and scale domestic AI startups in clinical and scientific sectors Direct equity funding paired with access to 1 million sovereign GPU hours Alliance Santé IA Programme Montpellier University Hospital & Adlin Science Build and deploy localized clinical research AI models across French hospitals Scaleway cloud hosting integrated with local university hospital data lakes The UK's AI Opportunities Action Plan highlights that operational continuity requires local control over compute resources. If AI models become deeply integrated into critical diagnostic pipelines, a loss of access to foreign-hosted models during a global crisis or diplomatic dispute could disrupt clinical operations. To mitigate this risk, the UK is establishing designated AI Growth Zones (AIGZs). These zones are designed to support computational clustering along high-impact geographic corridors, such as Slough to Cardiff or the West Midlands to South Wales. By coordinating planning consents, simplifying environmental reviews and integrating data centers directly into energy-system planning, these growth zones aim to secure the power and infrastructure required to run high-density clinical AI workloads locally. Engineering Sovereign AI in Healthcare: Architecture, Compliance, and National Strategies for On-Premises Clinical Deployment On-Premises Hardware Engineering and Compute Infrastructure Deploying a sovereign clinical AI platform on-premises requires high-density computing infrastructure capable of hosting and training models without relying on public cloud connections. Hardware manufacturers and system integrators have developed pre-validated, turnkey infrastructure platforms designed specifically for local enterprise deployments. HPE Private Cloud AI Developed in partnership with NVIDIA, HPE Private Cloud AI provides a fully integrated, turnkey computational platform. The platform ranges from entry-level installations featuring ProLiant Compute servers with NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs to high-density clusters utilizing the ProLiant Compute XD685. The XD685 incorporates direct-liquid cooling loops and supports NVIDIA Blackwell Ultra processors and the GB300 NVL72 platform. The compute cluster is integrated with high-performance GreenLake file storage to run a local data lake house. While the data plane runs entirely on-premises, the control plane is managed via HPE GreenLake. This hybrid orchestration allows clinical IT administrators to deploy models and manage resources through a unified dashboard while ensuring that protected health information remains within the local network perimeter. Dell AI Factory Dell's high-density computational portfolio is built around its PowerEdge XE server lineup. The PowerEdge XE8712 supports up to 144 NVIDIA Blackwell GPUs per rack and utilises direct-liquid cooling to manage thermal limits under heavy training loads. For air-cooled data centres, Dell offers the PowerEdge XE9780 and XE9785, which feature NVIDIA HGX B300 GPUs connected via 800 gigabits-per-second ConnectX-8 networking. These compute nodes are supported by the Dell APEX hybrid cloud management portfolio, providing a framework to scale on-premises hardware adjacent to active clinical storage systems. Cisco Nexus HyperFabric AI Cluster Cisco's approach to local sovereign AI emphasises network orchestration and automated fabrics. The HyperFabric platform pairs Cisco’s Silicon One architecture and Nexus 6000 series high-end Ethernet switches (operating at 400 and 800 Gb/s) with NVIDIA Tensor Core GPUs, BlueField-3 Data Processing Units (DPUs), and VAST Data storage solutions. This pre-validated design functions as a plug-and-play AI datacenter. The platform uses automated deployment tools to manage network pathways, minimize latency, and provide end-to-end visibility across the physical compute fabric. Palantir & NVIDIA Sovereign AI Reference Architecture This reference architecture provides an enterprise-ready operating system designed to run on-premises. The platform integrates Palantir’s Foundry services with local NVIDIA Blackwell Ultra GPU clusters and Spectrum-X Ethernet networking. Running on hardened Kubernetes container systems, this architecture is designed for healthcare systems that require low-latency inference and data sovereignty. It allows clinical organizations to deploy and manage AI systems locally, ensuring that patient data never crosses the hospital network boundary. Google Distributed Cloud (GDC) To support sovereign workloads, Google offers Google Distributed Cloud, which brings its public cloud software stack directly to on-premises hardware. Operating on commercial off-the-shelf hardware and managed via Kubernetes, GDC can run in either connected or fully air-gapped modes. The air-gapped configuration isolates the physical deployment from the public internet. It runs independently and cannot be remotely shut down by Google, satisfying national security and high-risk regulatory requirements. In Europe, Google collaborates with local operating partners like S3NS in France to deliver these isolated environments, aligning their operational resilience with SecNumCloud and European sovereignty standards. Technical Security Mechanics: Confidential Computing and Attestation To prevent privileged system administrators or compromised hypervisors from inspecting sensitive patient data, sovereign AI architectures utilise hardware-enforced confidential computing. This approach relies on Trusted Execution Environments (TEEs), which are hardware-isolated enclaves in system memory managed directly by the CPU. Technology Paradigm Isolation Granularity Encryption Mechanism Remote Attestation Basis Key Target Use Cases Intel SGX (Software Guard Extensions) Application-level; creates encrypted user-space enclaves in memory Hardware-enforced memory encryption engine inside the CPU Code measurements (MRENCLAVE) and signer identity (MRSIGNER) Modular application components and cryptographic key vaults Intel TDX (Trust Domain Extensions) Virtual Machine-level; isolates guest VMs in secure Trust Domains Secure Arbitration Mode (SEAM) shielding guest memory Intel SGX/DCAP cryptographic quotes checked via root CA Turnkey container runtimes and VM-based model training AMD SEV-SNP (Secure Encrypted Virtualization-Secure Nested Paging) Virtual Machine-level; isolates guest VMs with memory integrity Independent hardware AES keys managed by AMD Secure Processor Hardware-signed report containing hypervisor mapping logs GPU-accelerated workloads, data lakes, and private cloud nodes By utilising these TEEs, a clinical AI platform can encrypt patient data in memory during active processing, protecting it from host-level threats. In a clinical context, this prevents unauthorized access by privileged insiders, such as system administrators, who might otherwise inspect decrypted payloads or model weights. This attestation sequence ensures that sensitive clinical data is only processed by verified, unmodified hardware enclaves. This framework is illustrated by Rapha’s clinical AI edge appliances, which utilise Intel SGX and TDX paired with TPM 2.0 to verify platform integrity. The system verifies code measurements (MRENCLAVE), signer identity (MRSIGNER), and platform configurations against Intel's root certificate authority. Only after verifying this cryptographic evidence does the platform release the necessary decryption keys, allowing clinical training and transaction settlement on the Polygon mainnet via RaphaClearingVault. By isolating workloads at the hardware layer, confidential computing enables secure collaboration across clinical boundaries. For example, multiple healthcare institutions can participate in federated learning studies to train models without centralising their patient datasets. Each hospital trains the model locally within its own confidential enclave. The resulting model updates are encrypted and sent to a central server, where they are aggregated inside a secure TEE, protecting both patient privacy and model weights from unauthorized inspection. Architectural Implementation Patterns and Local Operations Deploying a sovereign AI platform requires a modular software architecture to manage model lifecycles and enforce security boundaries. A key reference design is the MAGS-SLH Sovereign pattern, which coordinates specialized AI agents while maintaining human control. The central Core Engine coordinates tasks and delegates execution to the Crew Agent Manager. The Crew Agent Manager instantiates specialized, ephemeral AI agents inside isolated runtimes to perform specific tasks, such as parsing an incoming diagnostic report, and terminates them immediately upon completion. By destroying these containers after use, the platform minimises the persistent attack surface and reduces the risk of lateral compromise. To integrate human oversight into automated workflows, the architecture features a Human-in-the-Loop Arbitrated Cognitive Interface (HACI). HACI provides operators with visibility into model decisions, allowing clinical staff to inspect, modify, or reject sensitive recommendations before they are finalised. Additionally, every step, data access event, and model output is logged to an immutable, eIDAS-compliant ledger, providing signed, timestamped records to support clinical audits. Turnkey Conversational Interfaces and Privacy Grounding Within a sovereign network, a private conversational interface can serve as a primary portal to access local infrastructure. Clinicians and administrators can interact with the system using natural language queries—for example, directing the orchestrator to deploy a new LLM container or allocate specific GPU nodes to an imaging pipeline. Because the interface and underlying models run entirely on-premises, users can input complete patient histories and detailed clinical notes without risking data exposure. This enables the system to generate more accurate, context-aware summaries and recommendations. To minimise the risk of model hallucinations, which present compliance and clinical safety risks, sovereign architectures utilise retrieval-grounded systems with built-in validation layers. These systems use local vector databases to retrieve verified context from approved clinical guidelines, medical textbooks, or institutional knowledge bases. The model relies on this retrieved context to formulate its response, rather than generating answers from its training data. A validation layer then evaluates the output against safety metrics and confidence thresholds, escalating low-confidence results to human specialists. Local Clinical Workflows and Medical Imaging Integration Sovereign AI architectures integrate directly with existing hospital infrastructure, such as picture archiving and communication systems (PACS). For example, a local medical imaging pipeline can use containerized models to segment anatomical structures in real time: In this localised workflow, DICOM format medical images are stored on secure local disks and imported to the containerised environment. The NVIDIA VISTA-3D NIM container segments over 120 organs and anatomical structures on a local GPU cluster, using Triton Inference Server to optimise throughput and reduce latency. The resulting segmentation masks are audited by a local validation layer before being returned to the PACS viewer for clinician review, keeping all patient data inside the hospital network. This local execution model is supported by offline productivity tools like Meetily, which run transcription and clinical summarisation models directly on end-user devices. By processing audio locally, these applications eliminate the need for external data transit or vendor Data Processing Agreements (DPAs), satisfying privacy-by-design requirements under GDPR Article 25. To support on-premises data protection, organizations deploy automated backup tools like Velero, configured to write to local, immutable storage targets. These configurations are restricted to prevent cross-region replication or data transfer to unauthorised locations. Every backup run, secret access event, and service account operation is cryptographically logged, providing audit trails to verify compliance. Operational Resilience, Recovery and the Human Factor Maintaining operational continuity is a critical requirement for sovereign clinical AI deployments. When high-performance models are integrated into daily clinical workflows, system outages can directly impact patient care and safety. Therefore, healthcare organisations must shift from a purely preventive security posture to a recovery-oriented resilience model. To manage operational risks and eliminate single points of failure across the local hardware stack, clinical IT teams utilise Failure Mode and Effects Analysis (FEMA). FEMA processes evaluate how hardware dependencies or network disconnects affect clinical services, establishing automated failovers to maintain system availability. For example, if a local GPU node experiences a hardware fault during a real-time diagnostic scan, the cluster controller automatically migrates the containerised workload to a healthy node, ensuring continuous operation. To defend against cyberattacks, sovereign architectures utilize Isolated Recovery Environments (IREs). An IRE is an air-gapped, distinct computational vault isolated from the primary network. It contains verified immutable backups, clean deployment images for all core models and operational systems, and offline copies of recovery playbooks and license keys. If a ransomware attack compromises the active network, the IRE allows the healthcare system to reconstruct its primary clinical AI pipelines without relying on external connections. Furthermore, managing the human factor is critical to maintaining operational resilience. During network outages, clinical personnel must be trained on validated fallback processes to prevent operational disruption. If clinical systems are unavailable, staff should not resort to unsanctioned consumer apps like personal WhatsApp or Gmail accounts to coordinate care, as this can lead to data exposure and regulatory non-compliance. By combining hardware-enforced isolation, offline recovery environments, and structured operational training, clinical enterprises can protect patient privacy while ensuring continuous access to critical AI capabilities. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Valuation Architectures in Healthtech and Medtech: Discounted Cash Flow and Terminal Value Frameworks Valuation Architectures in Healthtech and Medtech: Discounted Cash Flow and Terminal Value Frameworks The valuation of healthtech and medtech entities represents one of the most complex exercises in corporate finance, requiring analysts to bridge the gap between long-term scientific development, binary regulatory approvals, capital intensive commercialisation and rapid technological obsolescence. Within a discounted cash flow (DCF) model, the terminal value is the single most critical and sensitive component of a company's total implied valuation, typically constituting between 60% and 80%, and frequently up to 75% of the total implied enterprise value. Because the terminal value compresses decades of future cash flows beyond the explicit projection window into a single figure, small adjustments to terminal-year assumptions can result in massive swings in valuation. For instance, a minor $100,000 reduction in normalised operating cash flow in the terminal year can translate into a $1,000,000 reduction in implied enterprise value when utilising a standard 10x exit multiple. This report provides an institutional grade analysis of how terminal value is formulated, adjusted and reconciled for healthtech, medtech, and digital health companies. Foundations of Terminal Value in Healthcare Valuations In corporate finance, the terminal value represents the present value of all free cash flows a business will generate beyond the explicit forecast period (typically five to ten years) under the assumption of a going concern. This value is estimated using two primary methods, each anchored in different financial theories and market inputs. The Perpetuity Growth (Gordon Growth) Model The perpetuity growth model treats a business as a growing perpetuity that generates cash flows at a constant, sustainable rate forever. The mathematical formulation is expressed as: TV = \frac{FCF_{terminal} \times (1 + g)}{WACC - g} Where: TV$ is the terminal value at the end of the explicit forecast period (t = n). $FCF_{terminal} is the normalised free cash flow in the final projected year of the explicit forecast period. g is the perpetuity growth rate, which must be lower than the discount rate to ensure mathematical convergence. $WACC$ is the Weighted Average Cost of Capital, representing the discount rate. The resulting terminal value must then be discounted back to the present day using the following formula: PV(TV) = \frac{TV}{(1 + WACC)^n} Where n represents the total number of years in the explicit forecast period. In practice, the perpetuity growth rate (g) is anchored to long-term macroeconomic metrics, typically ranging between 2% and 4% to reflect sustainable, long-run nominal GDP and inflation expectations. The Exit Multiple Approach The exit multiple approach is a market-relative method that assumes the business will be valued or sold at the end of the projection horizon at a multiple of a key financial metric. It is structurally simpler and highly favoured by investment banking practitioners because it incorporates real-time market sentiment. The terminal value under this approach is formulated as: TV = EBITDA_{terminal} \times \text{Exit Multiple} Where: EBITDA_{terminal} is the normalised Earnings Before Interest, Taxes, Depreciation, and Amortisation in the final year of the explicit projection. \text{Exit Multiple} is a valuation multiple (such as Enterprise Value to EBITDA) derived from comparable public trading companies or precedent transactions in relevant sub sectors. Valuation Divergence: The Medtech Lifecycle and the Biopharma Patent Cliff A fundamental risk in evaluating medtech and healthtech assets is the misapplication of generalised corporate valuation methodologies to highly specialised product lines. In particular, a sharp divergence exists between the cash flow profiles of medical devices and biopharmaceuticals. Commercial-stage pharmaceutical models are heavily influenced by the "patent cliff" or loss of exclusivity (LOE). When a blockbuster drug's patent protection expires, generic or biosimilar competition floods the market, causing a rapid and severe erosion of 80% to 90% of the branded drug's revenue within two to three years. A classic historical benchmark is Pfizer's Lipitor, which generated $13 Billion in annual revenue at its peak but lost over $10 Billion in revenue within just two years of patent expiration. Because a drug's commercial viability is strictly time-limited, applying a standard perpetuity growth rate of 2% to 4% is dangerous and systematically overstates the terminal value. Instead, analysts valuing biopharma portfolios utilise a Sum-of-the-Parts (SOTP) framework, projecting product-level cash flows directly through their respective LOE dates and modelling explicit, steep decay curves that transition the terminal value of that specific product to zero. To evaluate whether a pharmaceutical company's developmental portfolio can replace the revenue lost to upcoming patent expirations, healthcare analysts utilise the pipeline coverage ratio. This metric compares the probability-weighted peak sales of pipeline assets to the revenue at risk from LOE over the next five to seven years. A ratio below 1.0x signals a looming revenue gap that typically forces the company to engage in strategic M&A to acquire commercial-stage assets. For example, the pipeline coverage ratio for Merck's Keytruda, representing approximately $25 Billion in annual revenue at risk of patent expiration between 2028 and 2030, is a central focal point in healthcare equity research and serves as a major driver of strategic acquisition activity. In contrast, medical device (medtech) products do not generally experience binary legal patent cliffs that trigger instantaneous generic entry. While medical devices have significant development timelines (typically 3 to 10 years) and regulatory barriers to entry, they are characterised by evolutionary engineering. Rather than facing a sudden 90% drop in cash flows, a mature medical device is slowly superseded by newer, technologically superior iterations or incremental product-line extensions. Furthermore, medtech companies often rely on high-barrier moats, such as proprietary platforms with steep switching costs (the "installed base moat") or behavioural lock-in driven by specialised surgical training (the "behavioural moat"). Consequently, mature medical device companies can support a standard perpetuity growth rate or a stable exit multiple in their terminal year, provided their technology has been successfully commercialised and integrated into healthcare workflows. Feature / Dimension Biopharmaceutical Products Medtech & Medical Device Products Healthtech & Digital Health Terminal Value Approach Sum-of-the-Parts (SOTP) with zero/minimal terminal value per drug; cash flows modeled to explicit decay Standard going-concern TV (perpetuity or exit multiple) applied to consolidated commercial platforms Standard going-concern TV, heavily focused on recurring revenue and SaaS-based multiples Exclusivity Profile Binary patent cliffs; high risk of immediate 80-90% generic erosion at LOE Gradual technological obsolescence; protected by proprietary platforms and physician preference Low clinical obsolescence; primary risk is SaaS platform switching and rapid software iterations Reinvestment Intensity Extremely high R&D to replace expiring pipelines; heavy reliance on clinical trial capital Moderate capital expenditures for specialized tooling, localized manufacturing, and line extensions Low physical CapEx; high development expensing (capitalized software) to support continuous platform updates Typical Cash Flow Moat Intellectual property, regulatory exclusivity, and clinical publications "Razor/blade" recurring consumables, surgical training, and installed hardware bases High switching costs, system-wide workflow integrations, and proprietary data structures Illustrative Sum-of-the-Parts (SOTP) Valuation Framework For diversified healthcare and pharmaceutical companies, corporate-level DCF models are highly insufficient because they obscure these divergent lifecycles. Instead, a Sum-of-the-Parts (SOTP) framework is utilised, which breaks the enterprise down into distinct commercial, pipeline, and corporate segments: \text{SOTP Value} = \sum(\text{Commercial Product DCFs}) + \sum(\text{Pipeline rNPVs}) + \text{Platform Value} - \text{Net Debt} The table below outlines a standard institutional implementation of a SOTP framework for a mid-sized healthcare enterprise with a mixed commercial and developmental portfolio: Portfolio Component Operational Parameters & Exclusivity Profile Implied SOTP Value ($B) Percentage of Total Enterprise Value Product A (Commercial) Peak sales of $4B; LOE cliff in 2027; currently experiencing declining commercial cash flows 12.00 28.24% Product B (Commercial) Peak sales of $2B; LOE cliff in 2031; currently in high-growth commercialization phase 10.00 23.53% Product C (Commercial) Early launch stage; estimated peak sales of $3B; LOE cliff expected in 2036 15.00 35.29% Pipeline Asset 1 (Clinical) Phase III oncology asset; 60% transition Probability of Success (PoS); est. peak sales of $2.5B 4.00 9.41% Pipeline Asset 2 (Clinical) Phase II rare disease asset; 25% transition PoS; est. peak sales of $1.5B 1.50 3.53% Early Pipeline (Pre-clinical) Aggregated preclinical and Phase I assets, conservatively valued 1.00 2.35% Corporate Overhead NPV Net present value of unallocated G&A, corporate R&D, and structural costs -3.00 -7.06% Aggregated Enterprise Value Total intrinsic value of the operating enterprise 40.50 95.29% Corporate Cash & Debt Bridge Plus: Cash and cash equivalents ($2.0B) 2.00 4.71% Implied Equity Value Total net asset value allocable to equity shareholders 42.50 100.00% Multiple Dispersion and Sector Benchmarks (2025–2026) When applying the Exit Multiple Approach to medtech and healthtech entities, comparable company trading multiples serve as the primary baseline. However, the medtech market is highly heterogeneous; a cardiovascular implant manufacturer and a commoditised hospital supply distributor operate under fundamentally different margin profiles, growth rates, and regulatory risk categories. Applying a generalised industry multiple is a common and severe valuation error. Rather, the multiple must be tailored based on the company's size, sub sector and underlying growth profile. Scale-Based and Sub sector Valuation Multiples In the medtech and healthtech markets of 2025 and 2026, enterprise multiples demonstrate a clear positive correlation with company scale, which is often termed the "size premium". Larger entities command premium multiples because of their diverse product portfolios, established distribution channels and lower execution risk. Conversely, in the broader healthcare space, service-oriented businesses have experienced multiple contraction, with median public healthcare services EV/EBITDA multiples declining to approximately 11.5x in 2026 from 14.5x in 2025. Scaled Financial Metric Pure-Play Medical Device Multiple Medtech Software / Digital Health Multiple $1M – $3M EBITDA 6.7x EV/EBITDA 8.2x EV/EBITDA $3M – $5M EBITDA 8.3x EV/EBITDA 10.2x EV/EBITDA $5M – $10M EBITDA 10.4x EV/EBITDA 14.4x EV/EBITDA $10M+ EBITDA (Mid-Market) 10.0x – 15.0x EV/EBITDA 14.0x – 18.0x EV/EBITDA $100M+ EBITDA (Large-Cap) 15.0x – 21.0x EV/EBITDA 18.0x – 25.0x EV/EBITDA $1M – $5M Revenue 3.6x EV/Revenue 5.0x – 8.0x EV/Revenue $6M – $10M Revenue 4.4x EV/Revenue 6.0x – 10.0x EV/Revenue $10M – $50M Revenue 5.0x EV/Revenue 8.0x – 12.0x+ EV/Revenue $50M+ Revenue 5.0x – 7.0x EV/Revenue 10.0x – 15.0x+ EV/Revenue When assessing unprofitable or early-stage digital health systems, valuations heavily rely on forward-looking revenue multiples. In the lower-market wellness sector, multiples remain conservative, with the median EV/Revenue multiple for wellness and health companies sitting at 1.1x in early 2026, slightly below pre-pandemic levels. Underperforming or unprofitable European startups trade at highly discounted ranges of 3.0x to 4.0x revenue, while general medtech in Europe commands 4.0x to 6.0x revenue, and AI-driven healthcare solutions trade at premiums of 6.0x to 8.0x+ revenue. Public trading reference benchmarks as of Q2 2025 illustrate the wide dispersion of multiples across different medtech business models: Intuitive Surgical: Command a highly premium valuation exceeding 20.0x EV/Revenue and 50.0x EV/EBITDA (with forward EBITDA multiples exceeding 40.0x), reflecting its dominant monopoly in robotic-assisted surgery and robust recurring software/service stream. Boston Scientific: Trades at 9.2x EV/Revenue and 35.0x EV/EBITDA (25.4x forward EBITDA), driven by its high-growth interventional cardiology portfolio. Stryker: Trades at approximately 7.0x EV/Revenue and 25.0x EV/EBITDA (22.0x forward EBITDA), representing a diversified orthopaedic and surgical player. Medtronic: Trades at approximately 4.0x EV/Revenue and 16.0x EV/EBITDA (14.0x forward EBITDA), reflecting slower organic growth. Baxter International: Trades at a discounted multiple of 2.2x EV/Revenue and 12.1x EV/EBITDA (9.2x forward EBITDA) due to lower growth profiles and more commoditised hospital hardware lines. Align Technology: Trades at 3.3x EV/Revenue and 15.2x EV/EBITDA (11.6x forward EBITDA). Peer Group Construction and Premium Drivers To avoid the "peer group trap," valuation specialists must construct comparable sets along three specific operational dimensions: Device Category Alignment (separating orthopaedic implants from cardiovascular devices, which have entirely different clinical margins and procedure volumes), Growth Profile Matching (grouping companies by organic growth rates, such as sub-3%, 3-6%, 6-10%, or 10%+), and Business Model Type (separating capital equipment-heavy companies from consumable-heavy razor/blade companies). The organic growth rate remains the single strongest predictor of multiple dispersion. For every percentage point of organic growth achieved above the industry average of 5% to 6%, a medtech company typically commands an additional 1 to 2 turns of EV/EBITDA. This relationship is non-linear and accelerates rapidly above 10% growth. This explains why Edwards Lifesciences, growing in the high-teens due to its transcatheter aortic valve replacement (TAVR) portfolio, historically trades at 20x to 25x EBITDA, representing 3 to 4 times the trading multiple of Medtronic, which is constrained by low-single-digit organic growth. Furthermore, the market rewards the recurring, high-visibility "razor/blade" business model with an additional 3 to 5 EBITDA turns relative to capital-equipment heavy peers. Finally, devices backed by regulatory barriers such as Premarket Approval (PMA) command significant premium multiples compared to those utilising the highly commoditised 510(k) pathway, which typically faces intense competitor density. Precedent Transactions and M&A Valuation Structuring In the medtech and healthtech sectors, strategic transaction multiples complement public comparable trading analyses by reflecting control premiums, cost and revenue synergies, and strategic asset positioning. Target Company Acquiring Strategic Entity Announced / Close Date Transaction Value ($B) Implied Revenue Multiple Implied EBITDA Multiple Key Strategic Catalyst & Valuation Premium Drivers Exact Sciences Abbott Laboratories 2025–2026 $21.0B ~7.0x N/A Cancer diagnostics leadership; capture of the highly valuable Cologuard franchise asset Penumbra Boston Scientific 2025–2026 $14.5B ~13.0x N/A High-growth thrombectomy market position; platform premium for vascular intervention portfolio Shockwave Medical Johnson & Johnson 2024 $13.1B ~18.0x ~54.0x High-growth Intravascular Lithotripsy (IVL) technology platform; strong margin profile Masimo Danaher Corporation 2025–2026 $9.9B ~6.6x ~18.0x (2027E) Leadership in pulse oximetry; valued at 15.0x on a post-synergized basis Wright Medical Stryker Corporation 2020 ~$5.4B ~5.0x – 6.0x ~35.0x Rapid expansion of extremities orthopedic portfolio; integration of localized sales forces Inari Medical Stryker Corporation 2025–2026 $4.9B ~8.0x N/A Capture of high-growth venous thromboembolism (VTE) clinical technology; 58% growth trajectory Intelerad GE HealthCare 2025–2026 $2.3B N/A N/A AI-powered enterprise imaging software; SaaS-based clinical workflow integration BTG plc Boston Scientific 2019 ~$4.2B ~7.0x ~25.0x Creation of a global interventional medicine platform; specialized drug-eluting bead technology Valuation Risk Mitigation: Earn-Outs and Contingent Value Rights Because medtech and healthtech companies are highly sensitive to regulatory clearances and clinical trial outcomes, M&A transactions frequently employ advanced structuring mechanisms to bridge valuation gaps between buyers and sellers. These mechanisms directly impact the cash flows projected in a transaction-based DCF. In life sciences and medical device transactions, earn-outs often comprise approximately 40% of the total potential deal value. Under these structures, a portion of the purchase price is held back and paid post-close only upon the achievement of specified clinical, regulatory, or commercial milestones. An example includes Medtronic's acquisition of CathWorks, which structured up to $585 Million in post-close milestone payments. Similarly, Boston Scientific completed an acquisition featuring a $15 Million upfront payment coupled with a $10 Million milestone tied to achieving FDA 510(k) clearance, a $15 Million milestone tied to commercial execution, and ongoing commercial royalties. Contingent Value Rights (CVRs), securities representing future payouts if specific technical or commercial milestones are met, are also widely used. CVRs were utilised in approximately two-thirds of all 2025 life science deals, averaging over one-third of the total transaction value. For corporate carve-outs and tax-free parent divestitures of non-core medtech divisions, companies utilise a Reverse Morris Trust (RMT). A notable example is the $17.5 Billion transaction separating Becton Dickinson’s Biosciences & Diagnostic Solutions via an RMT structure with Waters. Terminal Year Normalisation and Reinvestment Mechanics A frequent error in DCF modelling is the failure to properly normalise the cash flow of the target company in the terminal year. The terminal year represents a "steady state" where the company's financial performance has leveled out to a sustainable, predictable growth rate. Projecting unadjusted or lumpy cash flows into perpetuity results in highly distorted valuations. Normalising Capital Expenditures and Depreciation A common modelling practice is setting Capital Expenditures (CapEx) equal to Depreciation and Amortisation (D&A) in the terminal year (CapEx = D\&A) under the assumption that a mature firm only needs to replace its existing asset base. In institutional practice, this is mathematically inconsistent and fundamentally incorrect for three reasons: Inflationary Disconnect: Depreciation is an accounting metric based on historical, unadjusted acquisition costs. CapEx represents current and future outlays. Because of inflation, the future cost to replace physical manufacturing assets or specialised cleanrooms will always exceed historical depreciation. Growth-Support Requirements: If a company's free cash flow is projected to grow in perpetuity (g > 0), it must expand its physical or capitalised asset base to support that growth. A business cannot grow its revenue and production volume forever without expanding its physical cleanroom footprint, tooling, or database servers. Productivity and Cost Curves: Physical equipment becomes more efficient and technology costs decline over time. However, this productivity gain rarely offsets the combined effects of inflation and the capacity expansion required for growth. To resolve this, the steady-state reinvestment rate (RR) must be explicitly tied to the perpetuity growth rate (g) and the expected Return on Invested Capital (ROIC): RR = \frac{g}{ROIC} Once this rate is established, the normalised Capital Expenditures in the terminal year must be modelled as slightly lower than the hyper-growth projection years (reflecting lower reinvestment) but must mathematically remain above Depreciation and Amortisation to support the perpetual growth rate: $$CapEx_{terminal} = D\&A_{terminal} + \left( Net \ Revenue_{terminal} \times RR \right)$$ In healthtech and SaaS-enabled digital health platforms, physical CapEx is typically low, but research and development (R&D) and capitalised software development behave as the operational equivalent of CapEx. Analysts must ensure that capitalised software development costs are normalised and offset by appropriate amortisation in the terminal year, avoiding the assumption that software can be maintained without continuous capitalised engineering investment. Valuation Architectures in Healthtech and Medtech: Discounted Cash Flow and Terminal Value Frameworks Normalising Net Operating Losses (NOLs) and Tax Rates Medtech and healthtech startups frequently accumulate substantial Net Operating Losses (NOLs) and research tax credits during their clinical trial and early commercialisation phases. These tax shields often result in an artificially low or zero cash tax rate during the explicit projection period. However, in the terminal year, these historical NOLs are typically exhausted. Modeling a low cash tax rate into perpetuity will overstate the terminal value. Institutional analysts utilise one of three solutions to normalize terminal-year tax structures: Projection Extension: Extend the explicit projection period until the accumulated NOLs are fully utilised, allowing the cash tax rate to naturally step up to the standard marginal corporate rate in the final years before calculating the terminal value. Immediate Terminal Normalisation: Assume that NOLs do not exist in the normalised steady state, modelling the full marginal cash tax rate (typically 21% for US entities) starting immediately in the terminal year. Enterprise Value Adjustment: Ignore the NOL tax shields within the free cash flow projections (modelling standard marginal taxes throughout the explicit period) and instead add the standalone net present value of the NOL tax shields as a non-operating asset in the final Enterprise Value-to-Equity Value bridge. Elimination of Amortisation and Non-Recurring Items To normalise the terminal year free cash flow, analysts must eliminate non-recurring restructuring charges, lumpy working capital movements and the Amortisation of Intangibles. Because the terminal period assumes a steady-state going concern with no further finite-lived acquisition activities, amortisation of acquired intangibles should be removed from the terminal year cash flow. This ensures that the terminal FCF growth rate is normalised to a realistic 2% to 4% range, rather than carrying over an unsustainable 15% to 20% growth rate from the explicit projection period. Alternative Approaches for Pre-Revenue and Early Stage Valuations For clinical-stage medtech firms and pre-revenue digital health platforms, traditional corporate-level DCF models fail because they cannot handle negative EBITDA and high binary clinical or regulatory risks. Instead, valuation professionals rely on two primary alternative frameworks: Risk-Adjusted Net Present Value (rNPV) The rNPV framework is the gold-standard methodology for clinical-stage assets. Instead of adjusting for binary developmental risk by inflating the discount rate to an arbitrary venture-capital level (which can double-count risk), the rNPV model directly adjusts the projected commercial cash flows by the historical probability of achieving regulatory success at each phase gate. The rNPV is formulated as: rNPV = \sum_{t=0}^{N} \frac{CF_t \times P(success\_to\_year\_t)}{(1 + r)^t} Where: CF_t is the projected commercial cash flow in year t (incorporating R&D and clinical costs as negative cash flows, and commercial revenues as positive cash flows). P(success\_to\_year\_t) is the cumulative probability that the asset will survive all intervening clinical and regulatory hurdles to remain active in year t. r is a moderate, risk-adjusted discount rate (typically 8% to 12%), reflecting only the cost of capital and market risk, since clinical failure risk is already captured in the probability weights. Applying a high venture-stage discount rate (15% to 30%) alongside probability weightings is a common valuation error that systematically understates the pipeline asset's value. The probability adjustments in these models are based on historical transition success rates, which vary by therapeutic area and regulatory pathway: Development and Regulatory Milestone Phase Transition Success Rate Cumulative Probability from Pre-Clinical Pre-Clinical Development ~60.0% 60.0% First-in-Human / Phase I Trial ~65.0% ~39.0% Pivotal Trial / Phase II Trial ~35.0% ~14.0% FDA Submission / Phase III Trial ~60.0% ~9.6% (IND to Approval) FDA 510(k) Clearance / Approval 85.0% – 95.0% ~8.0% – 9.0% Intangible Asset and Comparable Financing Valuations When pre-revenue startups lack the visibility to build reliable cash flow projections, alternative asset-based or market-based approaches are utilised: Intangible Asset Valuations: This approach values the company based on its intellectual property portfolio, pending or approved regulatory dossiers (such as a 510(k) clearance or CE mark technical files), and clinically published safety and efficacy records. For example, a cleared 510(k) regulatory asset has an established direct value of $5 Million to $50 Million+ based on avoided development costs and speed-to-market. Comparable Financing Valuations: This approach benchmarks the company's valuation against recent financing rounds (such as Series A or Series B rounds) completed by similar peers in the same clinical sub sector. Terminal Value Growth Rate Assumptions and Analytical Reconciliations In corporate finance, terminal growth rates (g) must be set at or below the long-run nominal growth rate of the host economy to prevent the business from mathematically outgrowing the entire economy in perpetuity. While standard models default to 2% to 3% for mature businesses, actual institutional valuation research reveals a wider dispersion of growth assumptions depending on the specific asset profile: The Standard 2% Baseline: Zacks Small Cap Research's valuation of Cosmos Health (focusing on digital health services and integrated wellness models) utilises a 2.0% terminal growth rate. This is in line with standard macroeconomic inflation targets and long-term GDP growth. The 3% Institutional Consensus: Equity research analysts at ABG Sundal Collier (ABGSC) consistently employ a 3.0% terminal growth rate in their medtech valuations. For example, in their coverage of Ossdsign (scaling towards profitability), ABGSC applied a 3.0% terminal growth rate coupled with a 10.0% WACC. Similarly, their valuation of Q-Free (traffic management and tolling technology) utilised a 3.0% terminal growth rate. The 3.6% High-Growth Scenario: PIU Medical's reference DCF model utilizes a 3.6% base case terminal growth rate. This sits significantly above the standard 2.0% to 3.0% range, reflecting the premium growth dynamics of specialised pharma and medical device divisions. The 4% GuruFocus Earnings Stage: GuruFocus utilises a default 4.0% terminal growth rate within a secondary 10-year terminal stage in its two-stage discounted earnings model. To handle fast-growers and abnormal growth patterns, the growth rate during the initial stage is capped between 5.0% and 20.0%. Explicit Mathematical Reconciliation To ensure internal consistency, analysts must reconcile the implied perpetuity growth rate (g_{implied}) from a chosen exit multiple, or conversely, extract the implied multiple from an assumed perpetuity growth rate. This reconciliation acts as a vital sanity check. To calculate the implied perpetuity growth rate from a chosen EV/EBITDA multiple, the perpetuity growth equation is rearranged: g_{implied} = \frac{WACC \times Multiple - \left(\frac{FCF_{terminal}}{EBITDA_{terminal}}\right)}{Multiple + \left(\frac{FCF_{terminal}}{EBITDA_{terminal}}\right)} Where: Multiple is the target EV/EBITDA exit multiple. \frac{FCF_{terminal}}{EBITDA_{terminal}} is the free cash flow conversion ratio of the company in the terminal year, representing how efficiently the firm converts operating earnings into distributable cash. Consider a high-growth medtech software platform valued at a 15x EV/EBITDA exit multiple, with a WACC of 8.0% and a terminal FCF conversion ratio of 65%: g_{implied} = \frac{0.08 \times 15 - 0.65}{15 + 0.65} = \frac{1.20 - 0.65}{15.65} = \frac{0.55}{15.65} \approx 3.51% The resulting implied perpetuity growth rate of 3.51% is realistic and sustainable, sitting at the upper bound of long-term nominal GDP growth and justified by the platform's recurring SaaS revenue streams. If, however, a commoditised orthopaedic company with a lower-margin profile is valued at a 12x exit multiple, with a WACC of 10.0% and a terminal FCF conversion of 40%: g_{implied} = \frac{0.10 \times 12 - 0.40}{12 + 0.40} = \frac{1.20 - 0.40}{12.40} = \frac{0.80}{12.40} \approx 6.45\% A perpetual growth rate of 6.45% is highly unrealistic, as it implies the low-margin company will eventually grow to become larger than the entire economy. This signals a fundamental mismatch: either the exit multiple is too high, the WACC is miscalculated, or the terminal-year cash flow normalisation is flawed. By continuously cross-checking these two terminal value methodologies, equity analysts and investment bankers can construct mathematically coherent, risk-adjusted valuation models that reflect the unique operational and regulatory characteristics of the healthtech and medtech sectors. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Sovereign Enterprise: Decoding NVIDIA's On-Premises Strategy and the Structural Shift in HealthTech, MedTech and Hybrid Cloud Architectures The global computing landscape is undergoing a structural realignment. Driven by the rapid scaling of generative artificial intelligence and deep learning, the historical trajectory toward centralised public cloud environments is being challenged by a highly optimised, decentralised paradigm. NVIDIA is at the forefront of this transition, promoting on-premises "AI Factories" and localised hardware architectures as the defining infrastructure for the next decade of technology deployment. This strategic pivot is rooted in the concepts of Sovereign AI and hyper-local execution, wherein nations and enterprises construct, run and govern artificial intelligence using local physical infrastructure, proprietary datasets, and tailored software stacks. This paradigm shift carries profound implications for highly regulated, data-intensive fields such as healthtech and medtech. Rather than representing the demise of cloud computing, NVIDIA's strategy is forcing a structural evolution toward a deeply integrated, highly resilient hybrid AI model. In this architecture, the cloud functions not as the sole execution engine, but as an orchestration plane, high-scale training hub, and remote governance layer. The Geopolitical and Regulatory Push for Sovereign AI The transition from centralised public clouds to local enterprise AI factories is accelerated by the global imperative for Sovereign AI. Sovereign AI represents a nation's or enterprise's capacity to produce artificial intelligence using its own physical infrastructure, data assets, workforce and business networks. This localised approach directly addresses the geopolitical necessity for physical and linguistic autonomy. Rather than relying on generic models hosted in foreign cloud environments, sovereign infrastructure allows public and private entities to train localised foundation models on region-specific datasets. This accommodates unique regional dialects, preserves indigenous languages through speech AI and integrates culturally specific clinical practices into medical systems. Ultimately, these specialised AI factories are becoming the foundational engine of modern digital economies, transforming raw clinical data directly into actionable medical intelligence. Historically, migrating healthcare workloads to public cloud environments presented severe regulatory and security obstacles. For instance, while an enterprise might use an on-premises Oracle RAC database in combination with dedicated hardware to guarantee HIPAA compliance, typical public cloud equivalents, such as the Amazon Relational Database Service (RDS), historically lacked the necessary compliance certifications. Such compliance disparities, coupled with concerns over data sovereignty, network latency and inconsistent performance for legacy applications, have historically discouraged healthcare providers from pursuing a hundred-percent public cloud migration. On-Premises Dominance in Clinical Diagnostic Imaging and Medtech For the medtech industry, which encompasses diagnostic imaging, surgical robotics, and software-defined clinical equipment, local compute is not merely a preference but a strict operational requirement. The clinical edge is characterised by high data throughput, stringent regulatory requirements and a zero-tolerance threshold for network-induced latency. Traditional cloud-based AI introduction of network round trips is incompatible with real-time surgical or interventional applications. This reality is reflected in market dynamics, where the on-premises AI solutions segment continues to command the largest revenue share in the diagnostic imaging market. Major medical technology vendors, including GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V. and Canon, heavily prioritise localised processing to maintain operational consistency and secure clinical workflows. For example, GE HealthCare is collaborating with NVIDIA to advance the development of autonomous diagnostic imaging and autonomous X-ray technologies by utilising physical AI. These systems utilise localised computing to process high-resolution imaging data at the point of care, eliminating the bandwidth bottlenecks and security exposure associated with uploading raw patient scans to the public cloud. Local Compute Architectures and Model Quantisation Mechanics To make localised compute practical at the desktop and clinical edge, hardware-software co-design has evolved to support powerful AI workloads without a server room or cloud connection. Platforms such as the NVIDIA DGX Spark, powered by the Grace Blackwell GB10 superchip, represent a new class of desktop agent computers. Equipped with 128 GB of coherent unified system memory and delivering up to 1 PetaFLOP of FP4 parallel throughput, the DGX Spark allows developers, researchers, and clinical institutions to prototype and fine-tune models containing up to 70 Billion parameters, and execute inference on models of up to 200 Billion parameters locally. The mathematical driver behind this localised capability is the advancement in model quantisation, particularly the transition from standard floating-point precision to lower-precision formats. The relationship between model parameter count, precision bit-width and memory footprint is defined by: M_{precision} \approx \frac{P \times b}{8} where M_{precision} is the model's memory footprint in gigabytes, P$is the parameter count in billions, and b is the precision bit-width. Through advanced quantisation techniques, a standard 70-Billion-parameter model that typically requires approximately 140 GB of memory at 16-bit precision is compressed to an FP8 format, reducing its size to 70 GB. By utilising the Blackwell architecture's native support for fifth-generation Tensor Cores and the NVFp4 format, the model size drops further to 35–40 GB. This compression allows multiple models, such as speech-to-text, large language models (LLMs), and text-to-speech engines, to run concurrently on a single local device. In practical clinical scenarios, this quantisation not only halves the memory requirement but also more than doubles token generation speeds while cutting response times from 170 milliseconds to 60 milliseconds. This computational efficiency enables the deployment of localised autonomous agents in clinical settings. Using the open-source agentic framework OpenClaw and the security-conscious OpenShell policy engine, developers can build sandboxed voice agents that automate clinical workflows and summarise patient interactions locally. To ensure cultural alignment and regional accessibility, these local platforms support regional speech pipelines, such as Hindi, Bengali, Tamil and Telugu recognition via AI for Bharat models and Magpie TTS, enabling real-time voice interactions that remain entirely within the local facility. Hardware Platforms and Operating Layers of the AI Factory To support the diverse deployment requirements of healthtech and medtech enterprises, NVIDIA has established a modular portfolio of hardware platforms, each tailored to specific operational scales. Platform Primary Target Environment Computational Specialisation & Core Capabilities DGX Platform Enterprise AI Factories Purpose-built system designed for large-scale model development, deep learning training, and high-performance enterprise deployment. HGX Platform Hyperscaler & AI Supercomputers High-density supercomputing architecture optimised for intense artificial intelligence training and high-performance computing (HPC) workloads. IGX Platform Clinical Edge & Medical Devices Advanced functional safety and enterprise-grade security platform designed for real-time edge AI in medical devices and surgical robotics. MGX Platform Modular Enterprise Servers Highly modular, flexible server architecture allowing enterprises to customize accelerated computing configurations within standard data centres. OVX Systems Industrial Digital Twins Scalable data center infrastructure optimized for physically-based OpenUSD simulations, rendering, and high-performance AI workloads. DSX Platform AI Factory Operating Layer Software portfolio designed to help partners build and run AI factories at scale, optimized for the lowest possible cost of tokens per megawatt. This hardware ecosystem is unified by the NVIDIA DSX OS, an operating layer designed specifically to manage AI factories. DSX OS provides a modular, composable by design software suite that helps partners bring infrastructure online, maintain runtime consistency across hybrid deployments, automate fleet health diagnostics and run production AI workloads reliably at scale. To optimise these hardware resources, enterprises deploy specialised software orchestration layers. For example, the NVIDIA AI Computing by HPE portfolio integrates NVIDIA Run:ai, which maximizes GPU efficiency through dynamic resource pooling and advanced orchestration across cloud, hybrid, and on-premises environments. This is coupled with HPE Data Fabric Software for multi-cloud data governance and HPE OpsRamp Software to simplify hybrid cloud operations, allowing clinical research organisations to run simultaneous AI modelling and computational science workloads. These collaborative hybrid AI solutions, aligned through partnerships with Red Hat and IBM, provide healthcare enterprises with a direct pathway to transition AI from laboratory pilots to highly secure on-premises production. Real-Time Clinical Edge Processing and Physical AI The convergence of AI with physical clinical environments has accelerated the development of Physical AI, systems that do not merely process data, but perceive, reason, and act within real-world settings. In the medtech sector, this is represented by medical devices that execute closed-loop sensing, perception, and control under strict safety constraints. To support these deterministic, real-time edge applications, developers utilize the NVIDIA Holoscan and NVIDIA IGX platforms. NVIDIA Holoscan is a specialised computational platform designed to optimize every stage of the high-performance signal-processing pipeline, enabling real-time AI inference and graphic visualisation on software-defined medical devices. By combining Holoscan with the IGX platform, such as the IGX 700 which delivers up to 1705 TOPS of AI compute, clinical institutions can process massive, high-bandwidth data streams with built-in functional safety. The integration of the Holoscan Sensor Bridge (HSB) enables sensor data to bypass the standard operating system layers, transmitting images and sensor feeds via UDP directly into GPU memory. This architecture eliminates CPU-based bottlenecks, enabling ultra-low-latency processing of live surgical streams. A prime clinical application is neurosurgery, where the IGX platform is utilized to generate real-time 3D stereoscopic depth maps from standard, single-lens (monocular) surgical camera inputs. Similarly, surgical robotics leaders are integrating IGX and Holoscan architectures directly into their robotic suites to assist clinicians in real-time navigation, surgical pathing, and anatomical segmentation. The Sovereign Enterprise: Decoding NVIDIA's On-Premises Strategy and the Structural Shift in HealthTech, MedTech and Hybrid Cloud Architectures The Fate of the Cloud: Disconnected, Air-Gapped and Hybrid Operations NVIDIA's on-premises expansion does not signal the demise of the public cloud. Instead, it is forcing a transition toward a hybrid AI architecture where the boundaries between local compute and cloud systems are fluidly bridged. In this hybrid paradigm, different workloads are distributed dynamically based on their specific performance, cost and security profiles. NVIDIA's own internal operations validate this hybrid model. NVIDIA utilizes DGX Cloud—its internal, multi-tenant AI environment deployed across major Cloud Service Providers (CSPs) and NVIDIA Cloud Partners—to execute large-scale frontier model pre-training, validate new infrastructure architectures, and run massive production workloads. Once these models and operational practices are proven inside DGX Cloud, they are converted into repeatable software, reference architectures, and containerized configurations that directly deploy to on-premises customer infrastructure. To prevent client attrition, public cloud hyperscalers are actively deploying hybrid extensions that project cloud management capabilities onto customer-owned hardware situated on-premises. Microsoft and Amazon Web Services have developed highly advanced portfolios to bridge this gap: Microsoft Azure Local and Foundry Local Microsoft has introduced Azure Local, 365 Local, and Azure AI Foundry Local to support fully disconnected, sovereign, and offline operations. Running on customer-owned, Arc-enabled physical hardware, this architecture allows highly regulated industries, defense, and healthcare providers to run Exchange, SharePoint, and advanced multimodal AI models completely offline within their own facilities. Using Foundry Local, developers can run local inference and manage model lifecycles through Kubernetes-native operations without any data leaving the physical premises. Organizations can operate completely disconnected from the internet, relying on local caching and removable storage for model updates, while maintaining Microsoft's cloud-native governance, policy enforcement and management standards. AWS Outposts and Hybrid Integration AWS Outposts serves as a physical compute and storage extension of the AWS cloud, allowing organizations to run services like Amazon EKS Anywhere directly inside private data centers. By integrating AWS Outposts with high-performance, GPU-optimised storage solutions from partners like Cloudian, Pure Storage, and Weka, healthtech enterprises can bypass standard network delays. This combination enables direct GPU-to-object storage data paths, allowing edge devices to achieve the sub-10ms inference latencies required for continuous patient telemetry, home-based virtual wards, and real-time clinical monitoring networks. Operational Specifications for Hybrid and Disconnected Environments Deploying enterprise-grade AI within secure on-premises boundaries requires precise alignment with hardware minimums and support policies enforced by cloud ecosystem providers. Specification Parameter Microsoft Azure Local (Sovereign Entry Configuration) AWS Outposts (Hybrid Storage/GPU Integration) Minimum Hardware Nodes Three physical nodes per cluster. Single or multi-rack custom configuration. Memory Allocation Minimum 96GB of RAM per node. Variable; supports custom GPU-to-object storage data paths. Processor Requirements Minimum 24 cores per node. Dedicated Intel Xeon / AWS Graviton with NVIDIA GPU integrations. Storage Infrastructure One 2TB NVMe drive per node and 960GB of boot disk storage. Integrates with validated platforms such as Pure Storage, Cloudian HyperStore, and Weka. Update Policies Allows maximum of six months behind on updates to support disconnected modes. Continuous management via standard AWS region control plane connections. Sovereign Disconnected Support SharePoint, Exchange, and Skype Server supported entirely offline until at least 2035. Local survival of EKS containerized services during WAN disconnection. Local Deployment Stack Windows Server 2025 Hyper-V, winget tool, local model cache directories. Local EBS, S3-compatible APIs, and local GPU acceleration interfaces. Physical AI, Virtual Wards and the 6G "AI Fabric" The potential of these hybrid and disconnected models is illustrated by the convergence of edge-cloud computing with next-generation telecommunications. At Mobile World Congress 2026, AWS, NVIDIA, and partner AI-SENSE demonstrated a Physical AI healthcare deployment utilising a Virtual Ward and Health Buddy application. Within this architecture, patients receive continuous clinical-grade vital signs tracking inside their homes via a network of local sensors, wearables, and connected medical devices. When local processing detects an anomaly, the system can trigger physical responses in the home, such as adjusting robotic beds or opening automated doors. This continuous monitoring framework operates through a highly integrated training and simulation pipeline: Training Phase: Domain-specific clinical large language models are trained on AWS GPU infrastructure, incorporating extensive patient population data and clinical guidelines. Simulation Phase: Before clinical deployment, patient care pathways and environmental responses are validated in a high-fidelity digital twin environment using NVIDIA Omniverse running on AWS GPU instances, such as G6e and G7e instances, powered by AWS Batch. Execution Phase: The AI-SENSE Agentic Network Framework orchestrates data and decisions across the local devices and clinical systems. Looking forward, this real-time coordination is expected to rely on 6G networks acting as an active "AI Fabric". Rather than serving as passive data pipelines, these networks will utilise the Agent-Model-Tools-Environment pattern, employing continuous Sense-Understand-Reason-Act-Learn loops to dynamically allocate processing resources across the device-edge-cloud continuum. Empirical Case Studies and Quantitative Outcomes The deployment of localised and hybrid AI computing models across clinical and scientific institutions has yielded documented improvements in research velocity, patient safety, and operational efficiency. Organization & Domain Infrastructure Technology Stack Clinical / Scientific Application Quantifiable Clinical & Business Outcomes The Guthrie Clinic (Rural Healthcare System) Dell AI Factory with NVIDIA, incorporating Dell PowerEdge servers, storage, and AI-ready PCs. Remote patient monitoring and automated fall prevention. Reduced patient falls with injuries by nearly 70%; achieved $7 million in operational savings in a single year. Wellcome Sanger Institute (Genomics & Biodiversity) Dell AI Factory with NVIDIA, powered by high-performance Dell PowerEdge XE servers. Large-scale DNA decoding and rapid genome assembly. Accelerated processing throughput to successfully sequence and assemble a complete genome every seven hours. Public Healthcare Provider (Clinical Diagnostics) HPE Private Cloud AI, featuring validated server worker nodes and GPU virtualization. Automated medical imaging diagnostic pipelines. Drastically reduced diagnostic imaging backlogs from three months down to one week. Showa University Institute (Neurosurgery Research) NVIDIA IGX 700 with Holoscan Sensor Bridge (HSB). Stereo 3D reconstruction from single-lens surgical video feeds. Delivered real-time 3D visualizations, bypassing operating system delays to process data with zero lag. AI-SENSE & AWS (Digital Health Partnership) AWS Outposts, EKS Anywhere, and AI-SENSE Agentic Network Framework. Virtual Wards and Health Buddy conversational edge assistants. Achieved sub-10ms inference latencies for real-time patient home-care monitoring. Structural Trajectory of the Healthcare Technology Market NVIDIA’s promotion of on-premises architectures represents a correction to the over-centralisation of early cloud deployments. For healthtech and medtech organizations, this shift introduces an operational landscape defined by data sovereignty, physical edge execution and hybrid orchestration. Rather than rendering cloud computing obsolete, this model establishes a mature division of labor between edge and cloud platforms. To successfully navigate this transition, enterprise technology leaders must design their systems to align with this hybrid paradigm. Real-time surgical robotics, point-of-care diagnostic imaging, and local patient monitoring should be anchored on dedicated edge processors that bypass public cloud routing entirely. At the same time, regional clinical workflows, model fine-tuning, and secure data storage can be executed in turnkey private clouds or disconnected hybrid environments. By standardising on containerised micro-services and utilising advanced model quantisation, healthcare technology providers can build highly secure, portable, and clinically resilient systems that protect patient data while delivering real-time clinical support. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

This Week in European MedTech and HealthTech: 19th June 2026 Here's what's moved in European HealthTech over the past week, with the sector's attention firmly on Amsterdam. European HealthTech The headline is HLTH Europe 2026, running 15–18th June at the RAI Amsterdam under the theme "Step Outside". 5,000+ attendees from 50+ countries, one in three at C-suite level. It's the dominant gathering of the week, with company announcements (product launches, partnerships, research) being refreshed daily on the show floor and the Health Transformation Summit convening 200+ payer/provider CEOs and policymakers. Funding On funding, the standout was Semble's £30M Series C, led by Revaia with Partech and Octopus Ventures, to expand its open, interoperable clinical platform into France and larger European groups. Around it, a cluster of smaller AI-led rounds: 01Health ($15M Series A, specialist healthcare infrastructure, UK), Uncovr ($7M for surgical AI handling post-op documentation and workflow), OurMind (€2.1M, Dutch, clinical admin automation), TurnUp (€2M, Ghent, reducing no-shows for medical/dental practices), and Nanordica Medical (€1.6M, Estonia, antibiotic-free chronic wound care). On the capital-formation side, Thena Capital closed a £45M debut fund, led entirely by female GPs, to back up to 25 early-stage health and MedTech startups. Tech.eu data shows capital concentrating into larger, commercial rounds, led by the UK (€2.5Bn), Switzerland (~€1.0Bn) and Finland (€881M). Regulation Regulation produced the most friction. A political agreement on the Digital Omnibus amending the EU AI Act confirmed that AI medical devices will stay subject to parallel compliance under both the AI Act and MDR, a blow to MedTech Europe, which had lobbied for sector-specific rules only. Industry is mobilising to simplify the overlap, which Parliament estimates could save up to €3.3Bn annually. More positively, the EMA launched an innovation pilot for Class III and implantable devices, seen as a step toward a US-style breakthrough-device pathway. And the UK MHRA published draft Medical Devices (Amendment) Regulations 2026 introducing an "International Reliance Pathway", letting devices already cleared by trusted regulators (e.g. FDA) reach the GB market via a fast-tracked review. A quieter but important thread: diluted EU "AI literacy" training requirements are raising manufacturer liability exposure if clinicians misinterpret AI outputs, against a backdrop where the Philips Future Health Index 2026 reports 65% of European clinicians have increased medical-AI use. European MedTech Here's the MedTech-specific picture this week, distinct from the HealthTech/software developments, the action sat mostly in regulation and policy, set against HLTH Europe running in Amsterdam (15–18 June). Regulation was the dominant story. A political agreement on the Digital Omnibus amending the EU AI Act confirmed that AI-enabled medical devices will remain under parallel compliance from both the AI Act and MDR/IVDR, rather than sector-specific medical rules alone. MedTech Europe and industry leaders pushed back hard, calling it "an unnecessary layer of complexity"; the lobby is mobilising to simplify the overlap, which Parliament estimates could save the industry up to €3.3Bn a year. This sits on top of the Commission's December 2025 proposal to harmonise AI Act requirements with MDR/IVDR (observers expect adoption by summer 2026), and signals that high-risk compliance deadlines may slip to December 2027 (standalone systems) and August 2028 (AI embedded in regulated devices). Two more constructive regulatory moves: the EMA launched an innovation pilot for Class III and implantable devices, widely read as a precursor to a US-style "breakthrough device" pathway; and the UK MHRA published draft Medical Devices (Amendment) Regulations 2026 introducing an International Reliance Pathway, letting devices already cleared by trusted regulators (e.g. FDA) reach the GB market via a fast-tracked review. On the UK side, the government is also championing a new NICE national HealthTech access programme to speed adoption across the NHS, a meaningful market-access signal for device makers. On adoption and liability, the newly released Philips Future Health Index 2026 found ~65% of European clinicians have increased medical-AI use to save time, but experts flagged a growing manufacturer liability risk, because diluted EU "AI literacy" training requirements leave makers exposed if a clinician misreads an AI device's output. Device funding and deals were quieter and smaller-ticket on the European side this week, e.g. Nanordica Medical (€1.6M, Estonia) advancing antibiotic-free chronic wound care. The bigger context is momentum: 2026 MedTech M&A is tracking at a decade-high pace (PwC), with AI "tuck-in" deals expected to drive further acceleration, though this week's billion-dollar moves were largely US/global rather than European. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Clinical, Biophysical, and Market Evaluation of the Temple Wearable and its Real-Time Autonomic Entropy Biomarker Corporate Origin and Financial Architecture Deep-tech health monitoring has emerged as a major point of convergence for consumer electronics and longevity science. A notable project in this landscape is Temple, a neuro-technology and biological monitoring startup founded in 2024 by Deepinder Goyal, the founder and executive chairman of the Indian consumer internet giant Zomato. The initiative originated within Continue Research, a highly specialised, research-heavy division of Eternal, which serves as the parent conglomerate of Zomato and Blinkit. After operating in stealth mode for approximately two years, Temple emerged publicly in early 2026 following a fifty-four million dollar seed funding round that valued the startup at one hundred and ninety million dollars. Goyal positioned himself as the primary developer and "Patient Zero" for the technology, committing approximately twenty-five million dollars of his own capital to fund the early research and development cycles of the prototype. The development of Temple is closely tied to Goyal's personal interest in longevity and physiological optimisation. His personal routine, comprising blood tracking, fasting, meditation, hyperbaric chamber protocols and intensive supplementation, gradually focused on brain-specific circulation and cognitive health. This transition from consumer internet operations to human performance hardware reflects a broader industry trend of technology executives funding deep-tech research in areas like neuroscience and preventive healthcare. Conceptual and Biophysical Foundations of Entropy The selection of the term "Entropy" as Temple's flagship biomarker reflects a conceptual theme that spans Goyal's organizational and physiological philosophies. In corporate operations, Goyal has historically framed systemic challenges through the lens of thermodynamics, noting that the attrition and re-entry of employees creates a productive organizational "entropy" that propels institutional context forward. In the physical and biological domains, entropy represents the inevitable progression of a closed system toward thermodynamic equilibrium, chaos and structural decay. Living organisms, operating as open thermodynamic networks, must constantly perform work to capture "negative entropy" from their environments to maintain baseline internal order. Temple operationalises this biophysical principle by defining its trademarked biomarker, Entropy™, as the real-time metabolic and sympathetic demand under which the body operates. The metric is designed to quantify "the cost the body pays to be alive". A highly resilient, healthy organism is characterised by maintaining a low baseline level of autonomic entropy at rest, while retaining the capacity to surge and recover rapidly when subjected to physical or cognitive stressors. Conversely, an inability to return to baseline or a chronically elevated resting entropy state is clinically associated with physiological rigidity, chronic sympathetic dominance and accelerated biological aging. From a signal processing standpoint, physiological entropy is computed using non-linear algorithms such as Sample Entropy (SampEn) or Multiscale Entropy (MSE) applied to continuous pulse-to-pulse intervals (R\text{-}Rintervals) or arterial pressure wave fluctuations. Sample Entropy is mathematically defined as:cSampEn(m, r, N) = -\ln \left( \frac{A}{B} \right) where m represents the template length, r represents the vector comparison tolerance, $N$ is the total data length, B is the number of matching template vectors of length m, and A is the number of matching template vectors of length m+1. A higher entropy value indicates a complex, irregular and highly adaptive physiological signal, whereas a lower entropy value reflects physiological rigidity, chronic sympathetic over activation, or system failure. Anatomical Selection and Optical Sensing Modalities The Temple wearable diverges from the dominant wrist-worn consumer health-tech paradigm by targeting the temporal region of the skull. The hardware, constructed as a minimalist, forehead-worn headband or a sleek metallic clip positioned near the eye targets the superficial temporal artery. This artery is a branch of the external carotid artery and offers several major physiological advantages. First, the superficial temporal artery is densely innervated by the sympathetic nervous system. Second, because the temporal region lacks the thick adipose tissue found in peripheral limbs, the vascular bed sits exceptionally close to the skin surface. This physical architecture minimises the optical dispersion that typically degrades signal quality in wrist-worn PPG sensors. Furthermore, the temporal artery is largely unaffected by temperature-driven localised vasoconstriction, which frequently introduces noise into peripheral PPG signals during cold exposure. To capture these high-fidelity vascular dynamics, the Temple device uses Near-Infrared Spectroscopy (NIRS) and reflective-mode photoplethysmography (PPG). By continuously tracking cerebral blood flow (CBF) and arterial oxygenation in real-time, the system monitors fluctuations in arterial tone and blood volume. The physical stability of the skull during movement drastically reduces motion artifacts, enabling the capture of continuous, high-resolution pulse waves suitable for mathematical complexity calculations. Metabolic Cart Benchmarking and the Claim of Autonomic Superiority The central clinical claim surrounding the Temple device is that its proprietary "Entropy" biomarker tracks metabolic activity in real time and outperforms standard heart rate measurements when validated against a clinical metabolic cart. Traditionally, metabolic rate and energy expenditure (EE) are measured via indirect calorimetry using a metabolic cart. By evaluating the volumes of oxygen consumed (V\dot{O}_2) and carbon dioxide exhaled (V\dot{C}O_2), a metabolic cart calculates the exact caloric expenditure of the subject under various workloads. While precise, metabolic carts are highly restrictive, requiring patients to wear airtight face masks connected to stationary gas analysers. In attempts to bypass this logistical bottleneck, standard consumer wearables use heart rate as a digital proxy to estimate metabolic rate. However, heart rate is a lagging and often inaccurate indicator of real-time metabolic shift. Cardiac acceleration typically lags behind the actual cellular onset of physical exertion. Furthermore, heart rate is highly susceptible to non-metabolic confounding variables, such as psychological anxiety, caffeine consumption, dehydration and environmental heat stress. Temple’s Entropy biomarker addresses these limitations by leveraging the rapid sympathetic signalling of the temporal vascular bed. Because the temporal artery is directly connected to autonomic control loops, the complexity of its pulse-wave dynamics reflects immediate shifts in sympathetic tone and arterial tension. During graded exercise protocols, these microvascular changes occur almost instantaneously, aligning with real-time metabolic demands recorded by metabolic carts, whereas standard heart rate displays a pronounced physiological lag and susceptible cardiovascular drift. Clinical, Biophysical and Market Evaluation of the Temple Wearable and its Real Time Autonomic Entropy Biomarker Empirical Comparison and Market Positioning In empirical testing designed to evaluate the physical accuracy of the temporal sensor, Temple’s developers conducted comparative studies during high-movement athletic activities, specifically badminton sessions. The results demonstrated that the temporal placement achieved a level of precision comparable to clinical ECG standards, whereas wrist-worn PPG devices exhibited significant deviations due to motion-induced signal degradation. Device / Metric Heart Rate Output (BPM) Margin of Deviation from Standard Primary Structural Limitation Polar ECG Standard 141.4 0.0\% (Control standard) Requires continuous chest strap contact Temple Wearable 142.1 +0.49\% Head-mounted form factor restricts some headwear Wrist-Worn Tracker 120.5 -14.78\% Motion artifacts and capillary blood delay Temple’s technical focus and cranial form factor place the company in a distinct competitive niche relative to established consumer wearables. While mainstream devices focus on sleep tracking, step counts, or blood glucose, Temple targets direct neuro-hemodynamic and autonomic complexity metrics. Operational Domain Temple Wearable Ultrahuman Smart Ring Masimo W1 Watch Elite Athletic Trackers Anatomical Site Temporal forehead Finger Wrist Wrist / Chest strap Primary Biomarker CBF & Autonomic Entropy Blood Glucose / Metabolism Oxygen Saturation (SpO2) Heart Rate & Sleep Sensor Tech NIRS & PPG Optical & Bioimpedance Clinical Pulse Oximetry Optical PPG & ECG Primary Audience Elite athletes & longevity Metabolic health consumer Clinical-to-consumer wellness General fitness consumer Regulatory Status Non-medical prototype Consumer wellness device FDA-cleared clinical watch Varied consumer standards Neuroscientific Criticisms and Physiological Limitations Despite its commercial momentum, the scientific foundation of the Temple wearable has drawn substantial critique from clinical neurologists and physiological researchers. At the core of Temple's design philosophy is the "Gravity Aging Hypothesis" proposed by Goyal. This hypothesis suggests that the physical toll of spending upwards of sixteen hours a day in an upright posture, referred to as the "postural penalty", allows gravity to draw blood downward away from the brain. Goyal theorises that this persistent gravitational force subtly starves deep cranial centers, such as the hypothalamus and brainstem, of necessary blood supply over a lifetime, thereby accelerating cognitive decline and physical aging. Goyal has even described the device as functioning somewhat like a "miniaturised MRI scanner," although it lacks any diagnostic capacity. Medical experts argue that this premise neglects the fundamental physiological mechanism of cerebral autoregulation. Under normal physiological conditions, the body maintains constant cerebral blood flow across a wide range of blood pressures and postural shifts via highly coordinated myogenic and chemical feedback loops. Chronic, sub-clinical brain ischemia is not a typical characteristic of a healthy aging individual. Furthermore, critics emphasise a major anatomical disconnect: the Temple device is positioned to measure perfusion in the superficial temporal artery, which is a branch of the external carotid system supplying the scalp and face. The parenchyma of the brain is supplied entirely by the internal carotid and vertebral arteries. Therefore, a skin-mounted temporal sensor measures extracranial hemodynamics and cannot serve as a direct proxy for deep-brain tissue perfusion or the oxygenation of the hypothalamus. Critics have characterised the device as an expensive consumer novelty with no proven diagnostic capability. Additionally, the device has not received regulatory clearances from bodies such as the FDA or local health authorities, limiting its use strictly to non-medical personal wellness. Future Outlook and Commercialisation Strategy Temple's long-term commercialisation strategy depends on its ability to build credibility within both the scientific and consumer wellness sectors. Following its massive seed round, the startup has transitioned toward a commercial launch by opening applications for an early-access program. The first batch of one hundred production units was announced as ready to ship in May 2026. Temple is intentionally deploying these early units to a select cohort of athletes, founders, scientists, physicians and creators. This targeted distribution is designed to gather high-fidelity user feedback and generate a large, crowdsourced database of cranial PPG and autonomic entropy metrics. By mapping these long-term physiological trends across diverse lifestyles, Temple aims to compile empirical data to support its proprietary algorithms and potentially validate its underlying biophysical hypotheses. Ultimately, the startup's success will depend on whether it can successfully bridge the gap between wellness-driven personal bio-hacking and rigorous, peer-reviewed clinical validation. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors 10 Key Reflections from HLTH Europe 2026 Five thousand leaders, one in three of them holding an executive title, descended on the RAI Amsterdam from 15th to 18th June 2026 for HLTH Europe. The call to action this year was "Step Outside", a deliberate nudge to leave the comfort zone, look at familiar problems from unfamiliar angles, and find energy in collaboration across boundaries. For those of us who spend our days on the deal side of digital health, the phrase turned out to be an unusually accurate description of where the market is heading. The walls between sub-sectors, between strategics & start-ups and between European and global capital are coming down. Here are ten reflections from the Nelson Advisors team on what HLTH Europe 2026 tells us about M&A, partnerships and investment for the year ahead. 1. AI has crossed from narrative to numbers and that is reshaping the buy side For three years, "AI" was a slide that raised a round. At HLTH Europe 2026 the mood was different. The dedicated AI @ HLTH zone and the interoperability programming were packed, but the questions from the stage and the corridors were sharper: where is the measurable clinical outcome, where is the reimbursement and where is the gross margin once you strip out the compute bill. That maturity matters enormously for dealmaking. When buyers stop paying for promise and start paying for proven workflow integration, the market bifurcates. A small number of Healthcare AI companies with validated, deployed and revenue-generating products become highly contested acquisition targets, while a long tail of point solutions face a much harder funding road. Expect that gap to drive consolidation: the strongest platforms will acquire capability, data and talent, and the weakest will become acqui-hires or quietly wind down. For founders, the lesson from Amsterdam is blunt, defensible data assets and demonstrable ROI are now the currency that determines whether you are a buyer or are bought. 2. Interoperability is the quiet engine of Health IT M&A The headline sessions belonged to AI, but the connective tissue underneath every conversation was interoperability. The recurring framing, AI as the bridge that cleans messy data, translates formats and finally helps systems speak the same language, points to where a great deal of capital is about to flow. Health IT infrastructure is unglamorous, but it is sticky, recurring revenue and increasingly mandated by policy. That combination makes it a magnet for both strategic acquirers and private equity. We expect continued roll-up activity around data integration engines, FHIR-native platforms, clinical data warehouses and the middleware that sits between electronic health records and the new wave of AI applications. The European Health Data Space gives this thesis a regulatory tailwind: every provider and payer in Europe will need to move, standardise and share data at scale, and very few will build that capability in-house. Buyers who control the pipes will control the value, and that is a structurally attractive place to deploy capital. 3. Strategic acquirers are back in the room One of the clearest signals from HLTH Europe 2026 was the visible presence of corporate development teams from payers, providers, pharma and the larger HealthTech platforms. The Health Transformation Summit, bringing together more than 200 policymakers, provider and payer CEOs and innovators, was as much a private dealmaking forum as a policy debate. After two years in which financial sponsors dominated activity by default, strategics are leaning back in. Their motivation is partly defensive: incumbents cannot afford to let AI-native challengers capture the workflow layer between them and their patients or members. It is also partly offensive: acquiring a proven digital capability is faster and more certain than building one. For sellers, a re-engaged strategic buyer universe is the single most important driver of competitive tension in a process, and therefore of valuation. The presence of these teams in Amsterdam suggests 2026 and 2027 will see more strategic-led transactions than the recent past. 4. "Step Outside" is really a story about convergence The conference theme was about leaving your comfort zone, and the deal implication is convergence. The most interesting partnership conversations at HLTH Europe were not within sub-sectors but across them: pharma companies partnering with Healthcare AI firms on diagnostics and patient identification; retail and consumer brands moving into clinically validated care; medtech and Health IT companies fusing devices with software and data services. Convergence creates a rich environment for both partnerships and M&A because the strategic logic, acquiring a capability you cannot credibly build, is so clear. It also means buyers and targets increasingly come from outside the obvious peer set. A consumer technology company buying a remote monitoring business, or a pharma services group acquiring a patient-engagement platform, will look less surprising by the end of the year. Advisors and founders who define their competitive and acquirer landscape too narrowly will miss the most valuable counterparties. 5. Consumer HealthTech is growing up, and trust is the asset being bought Consumer HealthTech arrived at HLTH Europe in a more mature form than in previous years. The direct-to-consumer wellness narrative has given way to a focus on clinical validation, regulatory standing and, crucially, reimbursement pathways. That shift changes the M&A logic. The companies winning attention are those that have converted consumer reach into clinically credible, ideally reimbursable, propositions, in areas such as women's health, metabolic health, mental health and chronic disease management. For acquirers, the prize in this segment is twofold: distribution and trust. Building a consumer brand and earning patient trust is slow and expensive, which makes acquisition an attractive shortcut for incumbents seeking a direct relationship with patients. We expect continued pairing of capital-rich strategics with consumer-facing platforms that have the engagement but lack the balance sheet to scale clinically. Valuation in this segment will increasingly reward evidence and retention over raw user growth. Nelson Advisors 10 Key Reflections from HLTH Europe 2026 6. Healthcare cybersecurity has moved from cost centre to boardroom priority If one theme has graduated fastest from niche to mainstream, it is Healthcare Cybersecurity. The combination of relentless ransomware activity against hospitals, the expansion of connected medical devices and the tightening European regulatory regime, NIS2 and related directives, has pushed security to the top of the provider and payer agenda. That is showing up in budgets and, increasingly, in deal flow. Healthcare-specific security companies, identity and access management for clinical environments, medical device security and third-party risk management are all attracting investor attention. The investment case is compelling: regulatory mandates create non-discretionary demand, healthcare's threat surface is expanding, and the cost of a breach, in both fines and patient safety, is rising. We anticipate both venture and growth capital flowing into the sector and a wave of consolidation as broader security platforms acquire healthcare-specific expertise to serve a vertical that can no longer be treated as generic enterprise IT. 7. Capital is disciplined, not absent and the quality bar is high Anyone hoping HLTH Europe would signal a return to 2021-style exuberance left disappointed, and rightly so. The investment tone was disciplined. Capital is available, there is meaningful dry powder across European and global healthcare funds, but it is being deployed selectively and at valuations that reflect a reset from the peak. The practical consequences are visible across the market: well-run businesses with strong unit economics are raising and trading at healthy multiples, while companies that scaled on cheap capital without a path to profitability face down rounds, bridge financings, structured deals or sale processes conducted from a position of weakness. Secondary transactions and continuation vehicles are increasingly part of the toolkit as funds manage liquidity for limited partners. The message for founders is consistent with everything else heard in Amsterdam: efficient growth, clear margins and a credible route to profitability are what unlock both capital and optionality. Story alone no longer clears the bar. 8. European regulation is both friction and moat Few topics divided opinion at HLTH Europe more than regulation. The European Health Data Space, the AI Act and the Medical Device Regulation are real costs and real complexity, and plenty of founders voiced frustration at the pace and expense of compliance. But the deal-side reading is more nuanced. Regulation that is hard to navigate is also a barrier to entry, and barriers to entry create defensibility. Companies that have done the hard work of clinical validation, CE marking, AI Act conformity and data-governance compliance hold an asset that is difficult and slow to replicate. That defensibility is precisely what strategic acquirers pay premiums for. Regulation is also spawning its own investable category, the reg-tech, compliance and quality-management tooling that healthcare organisations need to keep pace. For investors willing to underwrite the complexity, Europe's regulatory environment is not only friction; it is the foundation of durable competitive advantage and a driver of M&A in the compliance layer itself. 9. Partnerships are the on-ramp to acquisition Perhaps the most practically useful reflection from HLTH Europe 2026 is how much dealmaking is now sequenced through partnership before it reaches acquisition. In an environment of valuation uncertainty and integration risk, large strategics are increasingly reluctant to make a cold acquisition of an unproven asset. Instead they are using commercial partnerships, pilots, co-development agreements and minority investments as a way to de-risk, to test the technology, the team and the cultural fit before committing to a full purchase. For founders this is a double-edged dynamic. A well-structured partnership can be the most efficient path to a premium exit, providing validation and a warm relationship with a natural acquirer. But partnerships can also lock a company into a single counterparty, suppress competitive tension and quietly transfer know-how. The companies that navigate this best treat partnerships strategically, building several relationships, protecting their data and IP, and keeping their options open so that any eventual sale is competitive rather than captive. 10. The exit outlook favours the prepared Finally, what does all of this mean for liquidity? The IPO window for European digital health remains cautious, and few expect it to swing fully open in the near term. That places the weight of exits on two channels: strategic acquirers, who as noted are re-engaging and private equity, which has both capital to deploy and a growing appetite for healthcare technology roll-ups built around recurring revenue and mission-critical software. Cross-border activity is a defining feature of this market, European assets are attractive to North American and increasingly Asian buyers and European strategics are looking abroad for capability. The overarching message from Amsterdam is that exit value will accrue disproportionately to the prepared: companies with clean data rooms, validated outcomes, strong security and compliance postures, efficient growth and a clearly articulated strategic fit for a defined set of acquirers. The market rewards readiness, and readiness takes time to build. Final Thoughts HLTH Europe 2026 captured a sector that has grown up. The exuberance has gone, replaced by a harder-edged focus on outcomes, economics and defensibility and that is a healthier foundation for dealmaking than the froth that preceded it. AI is the catalyst, interoperability is the infrastructure, regulation is the moat, and convergence is the strategic story tying it all together. For founders, investors and corporate development teams, the firms that "step outside" their comfort zone, looking beyond their immediate sub-sector for partners, acquirers and capital, will be the ones who create and capture value over the next cycle. The deals that define European digital health in 2026 and 2027 were, in many cases, first sketched in the corridors of the RAI. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Midjourney's Pivot from AI into Medical Hardware The Computational, Clinical and Financial Realities of Midjourney Medical: A Strategic Assessment of Whole-Body Ultrasonic Computed Tomography The entry of Midjourney Inc. into the medical hardware sector represents a significant shift for a company previously known for subscription-based generative artificial intelligence software. Unveiled by Chief Executive Officer David Holz on June 17th 2026, under the newly formed "Midjourney Medical" division, the "Midjourney Scanner" is proposed as a full-body, high-throughput ultrasonic imaging system designed to capture a comprehensive three-dimensional map of internal human anatomy in under 60 seconds. This sudden expansion into medical hardware is part of a broader corporate diversification program. The scanner is one of eight active initiatives at Midjourney, divided equally between four software projects and four hardware developments. The hardware pipeline is managed by Ahmad Abbas, who joined the company as Head of Hardware in late 2023 after serving as a Hardware Engineering Manager on Apple’s Vision Pro development team. Among these hardware initiatives is a walk-in spatial environment dubbed the "Orb," first announced in August 2024, highlighting the company's interest in physical, sensor-rich user experiences. Midjourney operates without venture capital or outside equity, self-identifying as a "community-backed research lab". While this corporate structure protects the company from external investor pressure, a pivot into capital-intensive medical manufacturing presents significant financial risks. These developments are occurring alongside ongoing copyright litigation brought by major entertainment entities, including Walt Disney Company and Warner Bros. Discovery, which could impact the company's financial reserves and long-term capital allocation strategies. By entering the highly regulated medical device market, Midjourney is transitioning from a high-margin software-as-a-service model to a business with complex supply chains, strict compliance demands, and prolonged clinical validation cycles. Technical Architecture and Acoustic Design The physical design of the Midjourney Scanner replaces the dry, enclosed bore of standard diagnostic machinery with a vertical, liquid-immersion scanning tank. To initiate a scan, a user stands on a platform illuminated by a golden light pool, which descends into the water at a steady rate of five centimeters (two inches) per second. Water serves as the physical acoustic coupling medium, replacing the localized gels used in traditional ultrasound to ensure continuous wave transmission across the skin. As the platform lowers the user's body, it passes through a ring containing approximately 500,000 sub-millimetre sensors. These sensors operate as dual-channel acoustic units, dynamically transmitting and recording high-frequency acoustic waves from hundreds of angles. This multi-angle approach captures backscatter, reflection and transmission data through vertical cross-sections of the body. This sensor array generates massive real-time data streams, with a single second of scan data producing the information equivalent of roughly 500 hours of high-definition streaming video. Processing these raw acoustic signals into a coherent volumetric reconstruction requires over two petaflops of dedicated on-device computational power. The primary transducer hardware relies on semiconductor-based "Ultrasound-on-Chip" technology developed by Butterfly Network (NYSE: BFLY). Traditional ultrasound systems use fragile, expensive piezoelectric ceramic crystals that are physically tuned to narrow frequency bands. Butterfly's silicon platform integrates thousands of micro-machined acoustic transducers directly onto a complementary metal-oxide-semiconductor (CMOS) chip. This architecture allows a single sensor to electronically emulate linear, curvilinear, and phased array wave profiles. The first-generation Midjourney Scanner prototype integrates 40 of these Butterfly modules, with subsequent models planned to scale this number. The core reconstruction pipeline does not rely on generative AI models to construct the anatomy, avoiding the risk of synthetic hallucinations in the raw physical data. The tomographic reconstruction uses physics-based signal processing algorithms. Deep learning is used in the post-reconstruction phase. Once the physical acoustic data is resolved into a 3D volumetric map, neural networks perform anatomical segmentation and labeling. This software layer automatically identifies boundaries for fat tissue, muscle groups, skeletal structures, and visceral organs, allowing users to view a labeled AI overlay alongside the raw tomographic data. Physical and Computational Limitations of Whole Body USCT While the concept of an acoustic-based whole-body computed tomography scanner offers clear advantages—specifically the absence of ionizing radiation and strong magnetic fields—it faces fundamental physical and mathematical challenges. Chief among these is acoustic attenuation and impedance mismatching at tissue interfaces. Acoustic waves travel through different human media at varying velocities and attenuation rates. In soft tissues, such as muscle, liver, or fat, acoustic waves propagate with relatively low attenuation (ranging from 0.3 to 1.8 dB/cm at 1 MHz). However, when an acoustic wave encounters a boundary with a highly contrasting acoustic impedance, most notably bone or air, the physical behaviour of the wave changes dramatically. Because cortical bone attenuates acoustic energy at rates up to 50 times greater than soft tissue, and air interfaces reflect sound waves almost completely, traditional diagnostic ultrasound is physically blocked by the skeletal structure and gaseous pockets within the gastrointestinal tract. This physical limitation makes deep brain imaging through the skull, or detailed imaging of organs obscured by bowel gas or the ribcage, highly difficult. Furthermore, historical attempts to commercialise Ultrasound Computed Tomography (USCT) have been limited to highly homogeneous, non-osseous regions, such as breast tissue screening. In breast imaging, the absence of bone and major gas interfaces allows sound waves to pass through the tissue relatively unimpeded. Extending USCT to the entire human body requires resolving complex non-linear inverse scattering problems. Standard tomographic reconstruction algorithms assume that waves travel along straight paths, which is a reasonable approximation for X-rays in computed tomography. However, ultrasound waves undergo refraction, diffraction, multiple scattering, and phase shifts as they move through tissue. To generate an accurate, millimetre scale image, the system must solve a highly non-linear, partial differential equation (PDE)-constrained optimisation problem known as Full Waveform Inversion (FWI). To overcome these computational bottlenecks, Midjourney's hardware relies on substantial local computing power (over two petaflops). The company is also exploring physical neural operators, such as Physics-Informed Neural Networks (PINNs) and Fourier Neural Operators (FNOs), to accelerate these wave propagation calculations. However, even with advanced mathematical models, physics dictates that standard acoustic energy cannot easily penetrate dense adult bone or deep, gas-obstructed thoracic structures. Consequently, early iterations of the scanner are expected to show high-resolution details in peripheral areas like limbs, joints, and superficial muscle groups, but will likely struggle to match MRI resolution in the deep abdomen, thorax, and pelvic cavities. Strategic Alliance and Butterfly Network Financial Dynamics The commercialisation roadmap for the scanner relies on a licensing and co-development agreement with Butterfly Network. This partnership, established under Butterfly's licensing division (formerly known as Octiv and rebranded as Butterfly Embedded), was first disclosed in an SEC Form 8-K filing on November 17th, 2025. The agreement outlines up to $74 Million in expected milestone and licensing payments to Butterfly over a five-year term, presenting a significant commercial opportunity for the chipmaker. The financial impact of the partnership was realised in the fourth quarter of 2025, where it contributed $6.8 Million in licensing revenue to Butterfly. This cash injection helped drive Butterfly’s total quarterly revenue to $31.5 Million, marking 41% year-over-year growth and supporting the first positive net cash flow quarter in the company's history. Financial Metric / Period Q4 2025 Performance Q1 2026 Performance FY 2026 Financial Guidance Midjourney Contract Terms Total Revenue $31.5 Million (41% YoY Growth) $26.53 Million (25% YoY Growth) $117 Million to $121 Million (20% to 24% Growth) Up to $74 Million over a 5-year term U.S. Revenue $26.8 Million (55% YoY Growth) $21.4 Million (25% YoY Growth) Primary driver of growth via Embedded partnerships Co-development revenue recognized dynamically Midjourney Revenue Contribution $6.8 Million (Recognized in Q4) Major driver of U.S. revenue growth Implied sustained milestone payments Tied to licensing and co-development phases GAAP Gross Margin 67.3% (Driven by high-margin licensing) 68.9% (Upward trend sustained) Sustained expansion through software/IP licensing High gross margin profile of Embedded platform Adjusted EBITDA Loss $3.2 Million (Improved from $9.1M) Not Disclosed in detail Projecting loss of $21 Million to $25 Million Helps offset core R&D operating expenses Cash & Cash Equivalents $150.5 Million $138.0 Million Stable liquidity position for platform scaling Milestone-based execution risk remains This co-development model helps de-risk Midjourney’s hardware program by utilising an established semiconductor manufacturing supply chain. Butterfly's third-generation handheld probe, the Butterfly iQ3, serves as a validated foundation for the underlying chip design. This allows Midjourney to focus its resources on software, 3D spatial reconstruction, and the physical design of the submersion tank. However, the milestone-based payment structure introduces execution risks for Butterfly, as future revenue is tied to Midjourney hitting specific development, manufacturing scale, and regulatory targets. The Commercial Playbook: Spas as a Regulatory Sandbox To address the long timelines and high costs of obtaining medical device approval from the US Food and Drug Administration (FDA), Midjourney has designed a consumer-facing launch strategy that utilizes regulatory pathways for non-diagnostic wellness devices. The company is branding its physical locations as "Midjourney Spas" rather than clinical imaging clinics. By marketing the scanner's initial output as a "detailed body composition map" (measuring skeletal structures, body fat distribution, and muscle volumes) rather than a clinical diagnostic tool, the company can commercialise the scanner without immediate FDA diagnostic clearance. Strategic Phase Timeline Operational & Technological Focus Regulatory Context Phase I: Optimisation Mid-2026 to Mid-2027 Algorithm fine-tuning, hardware trials, second-generation prototype design. Internal research; no public deployment. Phase II: Spa Launch Late 2027 San Francisco Union Square (25,000 sq ft, 10 scanners, saunas, cold plunges). Consumer-wellness mapping; bypasses FDA diagnostic pathway. Phase III: Expansion 2028 Rollout of third-generation scanners with custom silicon across multiple cities. Accumulation of observational clinical data to support FDA diagnostic filings. Phase IV: Fleet Scale By 2031 50,000 scanners globally; target of 1 billion scans per month. Full therapeutic and diagnostic integration across medical systems. The first physical facility is planned to open near Union Square in San Francisco in late 2027. The spa is designed as a 25,000-square-foot space housing nine or ten scanners alongside high-end wellness amenities, including hot tubs, saunas, cold plunges, and a gym. This model aims to integrate full-body scanning into a casual wellness routine, encouraging users to undergo regular, repeating scans as a standard part of their self-care and longevity routines. During this initial consumer phase, Midjourney plans to refine its reconstruction algorithms and gather large-scale observational datasets. In 2028, the company plans to transition to its third-generation scanner, which will introduce custom silicon to improve resolution and image quality. This hardware update is intended to support formal FDA submissions, with the goal of securing clearances that allow the system to perform active medical diagnoses. The long-term roadmap is highly ambitious, aiming for a global fleet of over 50,000 scanners by 2031 with the capacity to conduct one billion scans per month. Holz claims that widespread, early-stage scanning could eventually prevent up to 30 percent of all global deaths and cut 50 percent of healthcare costs. He also suggests that over a ten-year horizon, these devices could expand from diagnostic imaging into therapeutic applications. This therapeutic capability points toward the potential integration of high-intensity focused ultrasound (HIFU) or micro bubble targeted therapies directly into the submersion bath, transforming the scanner from a diagnostic tool into an active treatment system. Midjourney's Pivot from AI into Medical Hardware Competitive Analysis of Whole-Body Screening The consumer-wellness scanning market is divided into two distinct approaches: high-end diagnostic magnetic resonance imaging (MRI) and multi-sensor, non-diagnostic physical mapping. Midjourney Medical plans to position itself at the intersection of these two models, aiming to offer the deep-tissue capabilities of an MRI with the speed and lower cost of a sensor-based wellness scan. Feature / Dimension Midjourney Scanner (Midjourney Medical) Prenuvo Whole-Body MRI Ezra Proactive MRI Neko Health Body Scan Imaging Modality Ultrasonic CT (Tomographic reconstruction) Whole-Body MRI (Magnetic Resonance) Whole-Body MRI & low-dose CT 3D Body Scan, Optical, Infrared, & localized Ultrasound Physical Mechanism Water submersion gantry with 500k sensors Closed magnet bore, dry environment Closed magnet bore, dry environment Light-based imaging chamber, dry environment Session Duration Under 60 seconds Approximately 60 minutes Approximately 60 minutes 10 to 15 minutes Direct Session Cost Low-cost positioning (To Be Disclosed) $999 to $2,499 per scan $1,350+ per scan $250 to $350 (£299 / €250-300) Primary Focus Volumetric anatomical & body composition maps Early-stage tumor detection, spinal & organ health Multi-organ cancer screening & brain health Skin cancer monitoring & cardiovascular risk factors Clinical Validation Strategy Spa-based consumer data loop transitioning to FDA filings 10-year, 100k-participant study (Hercules Research, Boston) 3+ years of clinical observational data collection Primary care integration, clinical studies (0.2mm skin tracking) Geographic Footprint San Francisco launch (Union Square, 2027) Expanding across USA, Canada, and London Expanding across major metropolitan areas in the USA Limited availability (Stockholm and London) In the premium MRI screening market, companies like Prenuvo and Ezra target high-income individuals and wellness advocates. Backed by high-profile investors and celebrities, these platforms provide detailed scans of internal organs and spinal health. However, their high pricing ($999 to $2,499 per session) and standard 60-to-90-minute scan times limit their accessibility. To establish clinical validity, Prenuvo launched a 10-year, 100,000-participant research study at the Hercules Research Center in Boston to track how whole-body MRI can predict significant diagnoses in asymptomatic populations. Similarly, Ezra has been compiling observational clinical data for over three years to evaluate the diagnostic value of screening asymptomatic populations. In contrast, Neko Health, co-founded by Spotify's Daniel Ek, operates at a lower price point, charging between $250 and $350 for a 15-minute exam. Neko Health relies on a dry optical chamber and localized sensors to track skin changes (down to 0.2 millimeters), vascular health, and basic cardiovascular metrics. While highly accessible, Neko Health does not perform whole-body internal cross-sectional imaging, meaning its diagnostic capabilities are primarily limited to superficial skin conditions and basic blood abnormalities. By utilising Butterfly Network's semiconductor-based ultrasound chips, Midjourney plans to offer cross-sectional, volumetric anatomical imaging at a speed and cost structure that directly challenges these models. The success of this approach depends on whether its 60-second submersion scanner can generate high-quality internal imagery that matches the clinical value of standard MRI systems. Systemic Clinical Concerns and the Incidentaloma Dilemma The proposal to deploy thousands of high-resolution whole-body scanners for regular consumer wellness use faces significant skepticism from the clinical community. The American College of Radiology (ACR) has issued clear statements advising against total body screening for asymptomatic individuals, noting that there is currently insufficient evidence to justify the practice. Professional medical organisations argue that there is no clear evidence that routine, whole-body screening is cost-effective or successful in prolonging life. The primary clinical concern centres on "incidentalomas", benign, asymptomatic abnormalities that are naturally present in healthy human anatomy, such as non-progressive renal cysts, benign liver hemangiomas, or harmless thyroid nodules. High-resolution imaging systems will inevitably identify these harmless variations, initiating a sequence of clinical challenges. Final Thoughts Because an imaging scan alone cannot reliably differentiate between a benign structural variation and a malignant lesion, flagging an incidental finding often triggers significant patient anxiety. To rule out serious pathology, the patient is referred back into the traditional medical system for secondary diagnostics, such as specialised laboratory testing, contrast-enhanced CT scans, or serial MRIs. In many cases, these findings lead to invasive needle biopsies or exploratory surgeries, which carry real risks of procedural complications, including infections, bleeding, and localised tissue damage. Critics argue that by offering open access to whole-body scanning in a spa environment, Midjourney's model could generate a high volume of false positives and clinically insignificant findings. Proponents of proactive screening argue that these systems establish individual anatomical baselines, allowing clinicians to detect real pathological changes earlier. However, from a public health perspective, the downstream costs of investigating incidentalomas could strain existing healthcare infrastructure. Resources could be redirected toward managing benign findings in worried, asymptomatic consumers, potentially reducing the capacity of clinics and hospitals to care for symptomatic patients with acute medical needs. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Economics of Clinical Inference: Analysing Tokenmaxxing and Its Systemic Hazards for HealthTech and MedTech in 2027 Tracing the Genesis of Tokenmaxxing and Gamified AI Overuse Tokenmaxxing emerged in early 2026 as a highly polarising workplace phenomenon within Silicon Valley engineering organisations. Defined as the deliberate maximisation of artificial intelligence token consumption, the practice was initially conceptualised by some management teams as a proxy metric for employee productivity and AI integration. The fundamental premise of tokenmaxxing is that higher token consumption correlates directly with greater utilisation of powerful AI capabilities, thereby indicating a more productive, "AI-native" workforce. To incentivize this behaviour, several prominent technology companies implemented internal leaderboards ranking employees by the volume of tokens they processed. At organisations such as Meta, Amazon, and Salesforce, software developers were subjected to peer-monitored dashboards and desktop widgets displaying their active spend on platforms like Claude Code and Cursor. Some business units even established "minimum expected spend" targets, such as $100 weekly on Claude Code and $70 on Cursor, effectively penalising engineers who did not consume enough automated computational resources. Proponents of the practice, such as developer Sigrid Jin, argued that maximising token consumption was the premier mechanism for realising the return on investment for AI services, recommending that organisations spend as much on AI tokens as they do on corporate real estate rent. However, the gamification of raw computational input quickly triggered the classic consequences of Goodhart's Law: when a metric becomes a target, it ceases to be a reliable measure of productivity. In an effort to secure favorable performance evaluations and climb corporate leaderboards, software developers began systematically gaming the system. Engineers engaged in performative token consumption by running several autonomous agents in tandem, inputting unnecessarily long prompts, and automating repetitive tasks on dummy projects that were never intended for production. Rather than driving actual corporate value, tokenmaxxing incentivised wasteful behaviour, leading to bloated codebases, developer burnout and severe platform outages caused by uncontrolled AI code generation. The transition to parallel agent architectures accelerated this trajectory. Developers like Tom Tunguz documented burning up to 250 million tokens in a single day by orchestrating multiple background agents to parallelize tasks such as pulling git commit histories, generating charts, querying error logs, fact-checking citations, and critiquing presentation flows. While this extreme automation demonstrated high throughput, critics labeled the resulting paradigm a performance-review trap. This environment often produced "dangerous token maxxers" who optimized raw input consumption without generating meaningful business outcomes. This practice incentivised slower, more complex developer workflows, such as prompting AI to write answers for easily accessible documentation, while driving up massive computational overhead. The Macroeconomic Costs and the Mid-2026 AI Cost Crisis The structural inefficiency of tokenmaxxing culminated in a widespread corporate "AI cost crisis" in mid-2026. While the cost of training foundational AI models continued to decline, operational inference costs escalated exponentially. This financial strain was primarily driven by the transition from standard Large Language Model (LLM) queries to agentic workflows. Unlike static query-and-response models, autonomous clinical and software agents run continuous, multi-step cognitive loops, writing code, executing tests, encountering errors, adjusting context windows and repeating the process. A single approved user task can trigger a cascade of internal queries, amplifying token usage by 8 to 15 times and in some complex agentic environments, up to 1,000 times. The financial ramifications of this unchecked consumption were staggering. The creator of OpenClaw, Peter Steinberger, reported that his development team amassed over $1.3 Million in token costs in a single month across approximately 100 coding agents. Industry reports also emerged of a mystery enterprise accidentally spending $500 Million on Claude AI APIs within a 30-day period. Research firm SemiAnalysis disclosed a Claude token run-rate of $10.95 Million annually for just 30 employees, representing an unsustainable cost of roughly $365,000 per employee on AI tokens alone. By late 2026, this fiscal haemorrhaging triggered a swift retrenchment among early adopters. Enterprise giants such as Microsoft, Meta, Amazon and Uber quietly scaled back their autonomous agent licenses and rolled back token leaderboard programs due to unmanageable cloud expenditures. To mitigate the damage, the industry began adopting dedicated cost-observability platforms, such as Revenium’s AI Insights, to scan transaction histories, identify circular agent dependencies, flag outdated models, and enforce financial "circuit breakers" on runaway autonomous processes. This paved the way for a transition in late 2026 and early 2027 toward "Inference Yield", a paradigm focusing on maximising the clinical or operational value generated per token, rather than the raw quantity of tokens consumed. Macroeconomic Metric or Asset Class Financial and Operational Scale (2025–2026 Data) Primary Systemic Drivers Reference Sources Enterprise GenAI Spend $37 Billion total ($12.5 Billion on Foundation APIs) Explosive year-over-year developer adoption of API endpoints Various Global 2000 Average LLM Budget Shipped from $7 Million (2025) to $11.6 Million (2026) Corporate mandate to scale autonomous agent integrations Various Typical Business Token Burn 1 Billion to 10 Billion tokens monthly (10x–13x YoY growth) Shift from static single-turn queries to agentic loops Various Google Token Processing Volume Over 3.2 Quadrillion tokens monthly (7x YoY growth) Massive scaling of consumer and enterprise search/RAG pipelines Various Steinberger OpenAI Bill $1.3 Million (603 Billion tokens monthly across 100 agents) Parallel deployment of active software development agents Various SemiAnalysis Running Cost $10.95 Million annually ($365,000 per employee) Highly specialized agent-based research and report synthesis Various Copilot Unit Economics Lost over $20 per user monthly on flat-rate inference Switched to usage-based billing models to stem losses Various Medtech Code Quality and Software Verification Under High AI Adoption As the market enters 2027, the spillover effects of tokenmaxxing present a severe and unique threat vector for the healthtech and medtech industries. While consumer software firms possess the financial and operational margins to absorb minor bugs and iterative software updates, medical technology companies operate within strict regulatory and clinical risk boundaries. High AI adoption and tokenmaxxing behaviours among healthcare developers introduce systemic risks that directly threaten product viability and regulatory compliance. The most pressing technical consequence of tokenmaxxing is the rapid deterioration of code quality and the escalation of technical debt. In environments characterised by high AI adoption, developer monitoring tools have documented an alarming increase of over 800% in code churn—the measurement of code lines deleted relative to code lines added. This extreme code churn occurs because developers, incentivised to maintain high token volumes, write less code manually. Instead, they rely on automated agents to churn out massive segments of code, which they then accept and commit without going through rigorous peer review or verification. For Software as a Medical Device (SaMD) and clinical decision support systems (CDSS), code bloat and unverified generative algorithms are catastrophic. Medical software development is governed by stringent international quality standards, such as the IEC 62304 framework, which mandates rigorous validation, risk assessment, and lifecycle documentation for software code. Bloated, AI-generated code introduces hidden logic errors and undocumented vulnerabilities that are exceptionally difficult to detect during standard unit testing. If a clinical decision support algorithm contains unverified, machine-generated code blocks, the risk of runtime errors, data corruption, and erroneous diagnostic outputs increases. This can directly jeopardise patient safety, expose manufacturers to extensive liability, and result in costly FDA recalls or warning letters. Furthermore, the financial instability introduced by runaway token consumption threatens the viability of early-stage digital health startups. Unlike large enterprise software firms, medtech startups typically operate on highly constrained capital reserves derived from venture capital or research grants. When software developers or bio-informaticians run unchecked agentic workflows—such as querying error logs, generating time-series charts, or synthesizing competitive research pipelines—they can easily execute parallel flows that consume hundreds of millions of tokens daily. A clinical analysis agent tracking global competitor announcements or medical property registries can easily consume 100,000 tokens before a single output is produced. Without strict oversight, runaway agents can deplete a startup’s operational capital within a matter of weeks, shifting critical resources away from clinical validation, safety trials, and regulatory filings. Clinical Safety, Position Bias and the "Lost-in-the-Middle" Hazard In clinical environments, the pressure to expand AI integration has led to "context-maxxing"—the practice of feeding raw, unedited, longitudinal patient records directly into an LLM's expanded context window. While state-of-the-art models support context limits of up to several hundred thousand tokens, their structural attention mechanisms possess critical limitations that introduce severe patient safety hazards. The fundamental architecture of transformer-based language models exhibits a strong positional attention bias. When an LLM is presented with a long sequence of text, its retrieval and reasoning accuracy is not uniform across the input. Instead, the model's accuracy forms a distinct U-shaped curve: it demonstrates high performance (frequently exceeding 80%) when the crucial information is located at the absolute beginning or the absolute end of the context window. However, when the critical clinical information is buried in the middle of a lengthy clinical record, the model's retrieval accuracy drops precipitously to below 40%. This architectural blind spot is known as the "lost-in-the-middle" phenomenon. In clinical practice, the consequences of this positional bias are life-threatening. If a physician uploads a multi-page medical record into an LLM to generate a diagnostic summary or treatment plan, and a critical detail—such as a drug-to-drug allergy, a history of anaphylaxis, or an obscure lab value—is located in the middle of the document, the model is highly likely to omit or ignore it. The model will not warn the clinician of this oversight; instead, it will generate a clinical recommendation that appears mathematically coherent but is clinically incorrect. Simply expanding the context window of the model does not resolve this issue, as research shows that increasing available context can degrade overall reasoning performance, particularly regarding temporal progression and rare disease prediction. To bypass the financial and safety risks of context-maxxing, healthtech firms in 2027 are increasingly utilizing "BriefContext," a map-reduce strategy published in npj Digital Medicine. Rather than feeding a massive patient record directly to the generative module, BriefContext partitions the long retrieval context into shorter, overlapping, dense segments (typically 128-token chunks with a sliding window of 20) and embeds them using advanced vector models like BGE-en-large-v1.5. Using cosine similarity to identify and isolate key passages, the framework runs a "Context Map" operation to create multiple, highly focused RAG subtasks, followed by a "Context Reduce" operation that collects and summarizes the parallel responses into a final, safe diagnostic output. This methodology achieves clinical accuracy that matches or exceeds full-context processing while utilising a fraction of the input tokens, demonstrating that structured middleware is far superior to raw context-maxxing. Architectural Parameter Cloud-Based Large Language Models (LLMs) Edge-Based Small Language Models (SLMs) BriefContext Map-Reduce Architecture Typical Operation Costs High: $100,000 – $1,000,000 annually per system Low: $5,000 – $50,000 annually per system High efficiency: drastically reduces token consumption Inference Latency Slow: 200 – 1,000 milliseconds Rapid: 50 – 150 milliseconds Variable: dependent on subtask mapping and aggregation Clinical Recall Profile Positional attention bias: drops below 40% in middle High in narrow domains; limited overall capacity High uniformity: eliminates lost-in-the-middle bias Compliance and Security High risk of data transmission/HIPAA leakage On-device: complete local data control and compliance Variable: dependent on underlying model hosting Clinical Reasoning Capacity Moderate: struggles with temporal EHR data and rare diseases Highly optimized for specific, narrow task parameters Structured: integrates complex multi-document clinical notes The Economics of Clinical Inference: Analysing Tokenmaxxing and Its Systemic Hazards for HealthTech and MedTech in 2027 DeSci Tokenomics, Federated AI and Regulatory Compliance Gateways The convergence of Decentralised Science (DeSci) and tokenised digital health platforms in 2027 has created new compliance challenges for medical technology companies. Organisations known as BioDAOs—such as Molecule AG and VitaDAO, leverage distributed ledger technologies, smart contract governance, and tokenised incentive structures to fund biotechnology research, manage intellectual property and coordinate clinical trials outside traditional academic and geographical constraints. By operating globally, DeSci initiatives aim to run decentralised clinical trials (DCT) more rapidly and economically than traditional US-based paths, bypassing what some describe as a monopolistic domestic research cabal. However, when these decentralised platforms implement token-weighted voting systems or patient reward structures, they run directly into strict federal healthcare regulations. Any digital health or DeSci company utilising token economics to reward patient behaviour or incentivise research participation must comply with the federal Anti-Kickback Statute (AKS) and the Beneficiary Inducement Civil Monetary Penalty Law (CMPL). The Anti-Kickback Statute prohibits offering or paying any "remuneration", which includes cash, digital assets, utility tokens, or in-kind services, to induce patients to order or receive items or services reimbursable by federal programs like Medicare or Medicaid. Violations are classified as criminal offenses, carrying potential fines of up to $100,000 and 10 years of imprisonment per occurrence, alongside mandatory exclusion from federal program participation. Similarly, the Beneficiary Inducement CMPL prohibits offering incentives to government-program patients that are likely to influence their selection of a particular healthcare provider. Violations carry monetary penalties of up to $24,164 per violation and potential False Claims Act liability. To avoid these penalties, healthtech companies must structure their incentive programs to fit within existing regulatory exceptions and OIG safe harbors. Under the OIG's De Minimis (Nominal Value) Exception, provided incentives are permitted only if they are not cash or cash equivalents, do not exceed $15 per individual item, and do not exceed $75 in the aggregate per patient annually. Importantly, the OIG explicitly states that tradeable utility tokens, stablecoins, and digital gift cards do not qualify as nominal non-cash items, as they are convertible to cash on open exchanges and can be diverted for general purchases. Consequently, decentralised tokenised incentive structures are highly vulnerable to regulatory enforcement action if they distribute tradeable assets to patients. To remain compliant, healthtech companies must restrict incentives to "in-kind" patient engagement tools—such as connected scales, blood pressure monitors, or mobile apps directly recommended by a licensed clinician, to promote treatment adherence or disease management. Regulatory Framework Core Legal Prohibition or Standard Maximum Financial or Criminal Penalties Approved Safe Harbour Exceptions Anti-Kickback Statute (AKS) Exchanging remuneration to induce referrals or orders under federal programs $100,000 fine, 10 years imprisonment, program exclusion Fit within personal services or clinical co-management safe harbors Beneficiary Inducement CMPL Offering patient incentives likely to influence provider selection $24,164 per violation, treble damages, False Claims Act liability Nominal Value Exception: capped at $15/item and $75/year (non-cash only) OIG In-Kind Care Safe Harbor Prohibits cash or cash-equivalent patient rewards Complete invalidation of protection under the CMPL and AKS Clinically recommended digital health technology (e.g., connected scales) Stark Law and Stark Exceptions Self-referral of Medicare/Medicaid patients for designated health services Refund of collected fees, civil penalties, exclusion from Medicare Fair market value compensation set in writing and advance, independent of referrals Section 501(c)(3) Inurement Prohibition of tax-exempt earnings directly benefiting corporate insiders Complete loss of tax-exempt status or excise taxes Non-profit hospital co-management fee plans with capped performance metrics Furthermore, when healthtech companies establish co-management or clinical trial agreements with medical professionals, they must satisfy the requirements of the Stark Law and the Anti-Kickback personal services safe harbours. Under these regulations, any financial compensation paid to a referring physician must be set in writing, signed by both parties and reflect fair market value for actual services rendered. Crucially, the compensation formula must be established in advance, objectively verifiable and strictly isolated from the volume or value of referrals or other business generated between the parties. In tax-exempt non-profit health systems governed by Section 501(c)(3) regulations, any compensation arrangement must also avoid private inurement or impermissible private benefit to corporate insiders. To navigate these structural, compliance, and clinical safety risks while preserving the benefits of collaborative AI, forward-thinking healthtech developers are turning to Decentralised AI (DAI) architectures. By integrating Federated Learning (FL) and Swarm Learning with secure multi-party computation (SMPC), hospitals and pharmaceutical firms can train diagnostic and predictive models collaboratively without transferring sensitive patient records. This decentralized learning approach is exemplified by initiatives like the MELLODDY project, which enables pharmaceutical consortia to train drug-discovery models on sensitive chemical datasets without exposing proprietary information. By training models locally on edge-based Small Language Models (SLMs) and transmitting only model updates, healthcare organisations can maintain absolute HIPAA, GDPR, and PCI-DSS compliance while eliminating the massive financial overhead of cloud-based tokenmaxxing. Strategic Leadership Recommendations for 2027 To remain viable and secure in the 2027 healthcare marketplace, healthtech and medtech executives must implement a series of structural, clinical and regulatory corrections. These adjustments must explicitly address the computational waste of tokenmaxxing, the clinical safety hazards of context-maxxing, and the strict legal parameters of healthcare tokenomics. First, corporate leadership must completely abolish input-based engineering metrics, such as internal token-usage dashboards and employee leaderboards. Tracking raw token consumption as a measure of productivity is a highly gameable metric that directly incentivises performative developer behaviours, code bloat, and uncontrolled code churn. Instead, engineering metrics must be re-centered on "Inference Yield"—the clinical and business value generated per token. All qualitative reasoning must be decoupled from token metrics, focusing instead on outcomes like clinical validation, software reliability, and adherence to IEC 62304 lifecycle processes. Second, digital health platforms must implement technical "circuit breakers" and comprehensive cost-observability tools across all development environments. These software boundaries should automatically identify and terminate runaway autonomous clinical or research agents, detect circular agent dependencies, and flag abnormal daily spend spikes. To avoid the astronomical financial drain of cloud APIs, developers should transition key clinical workloads to edge-based Small Language Models (SLMs) running locally on clinical workstations or medtech hardware. Local inference entirely bypasses cloud-based token billing while natively preserving patient privacy and compliance. Third, healthtech developers must transition clinical record synthesis away from raw context-maxxing to structured retrieval and middleware frameworks. To protect patients from the life-threatening omissions of the "lost-in-the-middle" attention bias, applications should mandate map-reduce architectures like BriefContext. By dividing long longitudinal patient records into overlapping, dense, local segments and processing them through map-reduce pipelines, developers can guarantee uniform information retrieval density without modifying the underlying weights of foundational models. Finally, healthtech founders and DeSci BioDAOs must ensure that their tokenomics designs comply strictly with federal Anti-Kickback, Stark, and CMPL guidelines. Companies must avoid distributing tradeable digital tokens, cryptocurrencies, or stablecoins to patients, as these assets are classified by the OIG as prohibited cash equivalents. Patient rewards must be restricted to nominal, non-cash, in-kind tools that directly support care coordination and treatment adherence. Any compensation paid to clinical investigators or co-management partners must be set at fair market value in writing, signed by all parties, and strictly isolated from referral volumes to avoid private inurement and illegal kickback schemes. By replacing performative tokenmaxxing with disciplined inference architecture and regulatory rigour, medtech firms can safely deploy AI innovations in 2027. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk